US Pat. No. 10,654,959

METHOD FOR PREPARING SUPERABSORBENT POLYMER

LG Chem, Ltd., (KR)

1. A method of preparing a superabsorbent polymer, the method comprising the steps of:performing crosslinking polymerization of a monomer mixture to form a water-containing gel polymer, wherein the monomer mixture includes water-soluble ethylene-based unsaturated monomers having acidic groups which are at least partially neutralized, a carbonate, a volatile organic solvent, a surfactant, and a foam promoter, and wherein an internal crosslinking agent is used in the crosslinking polymerization of the monomer mixture;
drying, pulverizing, and size-sorting the water-containing gel polymer to form a base polymer powder; and
additionally crosslinking the surface of the base polymer powder to form a surface-crosslinked layer, wherein a surface crosslinking agent is used in the crosslinking of the surface of the base polymer powder, and
wherein the surfactant is a silicone-based surfactant and is used in an amount of 0.00001% by weight to 0.00100% by weight with respect to a total weight of the monomer mixture,
the foam promoter is an inorganic acid aluminum salt, and
centrifuge retention capacity (CRC) in a physiological saline solution is 29 g/g to 35 g/g, absorbency under load (AUL) of 0.9 psi in the physiological saline solution is 17 g/g to 21 g/g, a vortex time is 30 seconds to 50 seconds, and absorbency under load of the superabsorbent polymer, as measured after swelling the superabsorbent polymer in the physiological saline solution under a load of 0.3 psi for 5 minutes and removing residual liquid under vacuum, is 18 g/g to 21 g/g.
US Pat. No. 10,655,215

TREATMENT METHOD USING A BEAM OF SINGLY- OR MULTIPLY-CHARGED GAS IONS IN ORDER TO PRODUCE COLORED METALS

1. A treatment process for coloring a metal, comprising:a) bombarding the metal with a beam of mono- and multicharged ions of a gas produced by an electron cyclotron resonance (ECR) source, wherein:
a dose of mono- and multicharged ions of the gas implanted per unit of surface area by the bombardment is in a range of between 1016 ions/cm2 and 1019 ions/cm2,
a single acceleration voltage is applied, said single acceleration voltage has a value in a range of between 5 kV and 1000 kV; and
b) performing a heat treatment for coloring the implanted metal, wherein:
the heat treatment is performed at a temperature of between 100° C. and 600° C. for an exposure time of between 1 min and 4 hours.
US Pat. No. 10,653,169

FOOD THICKENING AGENT, METHOD FOR PRODUCING FOOD THICKENING AGENT

Kent Precision Foods Grou...

1. A method for preparing a thickener, the method comprisinga) providing mineral water;
b) combining said mineral water with a salt of benzoic acid to produce a first mixture;
c) combining the first mixture with sodium hexametaphosphate to produce a second mixture, said second mixture being subjected to heat;
d) combining the second mixture with EDTA to create a third mixture, said EDTA being present in an amount effective to lower the water activity to 0.75 or below, said third mixture being subjected to heat at a higher temperature than said second mixture; and
e) adding a xanthan thickener to create a fourth mixture.
US Pat. No. 10,654,961

PEROXIDE-MODIFIED POLYETHYLENE, COMPOSITIONS, AND APPLICATIONS

Equistar Chemicals, LP, ...

1. A process for preparing a peroxide-modified polyethylene comprising the steps of:(A) preparing a first Ziegler-Natta-catalyzed polyethylene in a first reactor;
(B) transferring the first Ziegler-Natta-catalyzed polyethylene from the first reactor to a second reactor;
(C) admixing a first amount of an organic peroxide to the second reactor;
(D) reacting the organic peroxide with a polyethylene composition made from or containing the first Ziegler-Natta-catalyzed polyethylene, thereby coupling the polyethylene components and forming the peroxide-modified polyethylene; and
(E) collecting the peroxide-modified polyethylene
wherein the first Ziegler-Natta-catalyzed polyethylene is a linear low density polyethylene, having a melt index (ASTM D 1238) in the range of about 5.5 g/10 min to about 7.5 g/10 min, a density (ASTM D 1505) in the range of about 0.88 g/cc to about 0.925 g/cc, a tensile strength (ASTM D 638) in the range of about 1400 psi to about 2,000 psi, and an elongation at break (ASTM D 638) in the range of about 750% to about 1000%.
US Pat. No. 10,654,962

ACRYLIC FILM, METHOD FOR PRODUCING SAME, LAMINATE FILM, LAMINATED INJECTION MOLDED ARTICLE, AND METHOD FOR PRODUCING RUBBER-CONTAINING POLYMER

Mitsubishi Chemical Corpo...

1. An acrylic film comprising an acrylic rubber-containing polymer (G) and having a thickness of 30 to 300 ?m, in which a number of fish eyes that are 0.001 mm2 or greater in size is 130/m2 or fewer per 1 m2 of the acrylic film when a section having a light transmission ratio of 75% or less for light having a wavelength of 400 to 1100 nm is detected as a fish eye by using a surface inspection device,wherein the acrylic rubber-containing polymer (G) is obtained by a method comprising multi-stage polymerization steps including the following steps (1) and (2):
(1) a first stage polymerization step in which a first emulsion having a monomer mixture (a) containing 20% by mass or more of alkyl acrylate emulsified in water is supplied to a polymerization vessel, and
(2) a second stage polymerization step in which a second emulsion having a monomer mixture (b) containing 50% by mass or more of alkyl methacrylate emulsified in water is supplied to the polymerization vessel after the first polymerization step,
wherein a number average particle diameter of a dispersion phase is 300 ?m or less for the first emulsion and the second emulsion, respectively, and
an amount of a surfactant used for preparation of the emulsions is set at 0.5 parts by mass or more and 1.6 parts by mass or less relative to the total amount of 100 parts by mass of a monomer mixture in any polymerization steps of the multistage polymerization steps,
wherein at least one polymerization step (3) is included between the step (1) and the step (2), and the polymerization step (3) does not include an emulsifying step.
US Pat. No. 10,653,683

TIOTROPIUM INHALATION SOLUTION FOR NEBULIZATION

GLENMARK SPECIALTY S.A., ...

1. A stable inhalation solution for the treatment of a respiratory disease, the inhalation solution being suitable for administration with a nebulizer, the inhalation solution comprising:(i) tiotropium bromide;
(ii) citric acid;
(iii) sodium citrate;
(iv) sodium chloride; and
(ii) water,whereinthe inhalation solution is substantially free of preservative and complexing agent and has an osmolality of about 200 to about 500 mOsm/kg, and
the inhalation solution is contained in a prefilled container.
US Pat. No. 10,654,195

METHOD FOR PREPARING WASTE POWDER FROM GENERATIVE PRODUCTION PROCESSES

1. A method for preparing waste powder from generative production processes, by means of which three-dimensional objects are produced in layers from a powdery base material in that initially a first layer of said base material is applied to a construction platform, which first layer is then irradiated and hardened in accordance with the coordinates of a first plane of the object to be built using a laser or other source of radiation, wherein, after completion of processing in said first plane, the construction platform is lowered by the layer thickness of another plane and a new powder layer is applied, and wherein these process steps are repeated in accordance with the number of planes until a three-dimensional object is built, upon completion of which powdery material remains as waste powder outside the areas covered by the laser, wherein the waste powder is subjected to a mechanical treatment in that it is reduced to small pieces by means of a grinding mill, wherein the waste powder is reduced to a grain size which is smaller than an original grain size of the powder in its new condition.
US Pat. No. 10,653,172

NATURAL STILBENES AS SWEETENERS OR SWEETENER ENHANCER

Analyticon Discovery GmbH...

1. A sweetener composition comprising:(a) a component comprising an effective amount of a compound selected from the group consisting of Gnetifolin E and Piceatannol-4?-O-?-D-glucoside and mixtures thereof; and
(b) a separate component selected from the group consisting of: sucrose, glucose, fructose, rebaudioside A, rebaudioside D, rebaudioside M, and mixtures thereof; and
wherein said effective amount of said compound potentiates sweetness of said separate component (b).
US Pat. No. 10,654,964

COMPOSITIONS COMPRISING POLYETHER-URETHANE-UREA ADDITIVES FOR BLOCK RESISTANCE AND OPEN TIME

Dow Global technologies L...

1. A composition comprising: (a) a hydrophilic polyurethane comprising polymerized units of: (i) a water-soluble polyol having hydroxyl functionality from two to four and a weight-average molecular weight from 800 to 16,000; and (ii) an aliphatic polyisocyanate having isocyanate functionality from two to six; wherein said hydrophilic polyurethane comprises at least 85 wt % of polymerized ethylene oxide units; and at least one of: (b) a saccharide having at least 5 hydroxyl groups and Mw from 300 to 4,000; (c) a dispersant polymer having Mw from 700 to 50,000 and from 10 to 55 wt % polymerized residues of C3-C6 carboxylic acid monomer; wherein the water-soluble polyol comprises: (i) a water-soluble polyethylene glycol having a weight average molecular weight from 4,000 to 10,000, and (ii) an ethoxylated glycerol having weight average molecular weight from 800 to 1,600.
US Pat. No. 10,653,173

METHOD FOR MASKING UNPLEASANT TASTE

Analyticon Discovery GmbH...

1. A method for masking unpleasant, bitter, astringent and/or liquorice-like taste impressions of one or more artificial sweeteners in a food or pharmaceutical preparation, said method comprising adding dehydroabietic acid in an amount of about 1 ?M to about 500 ?M to said food or pharmaceutical preparation, wherein said food or said pharmaceutical preparation does not comprise caffeine, and wherein said dehydroabietic acid masks the unpleasant, bitter, astringent and/or liquorice-like taste impressions of said one or more artificial sweeteners contained therein, with the proviso that the food preparation is not a chewing gum.
US Pat. No. 10,653,685

PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THE TREATMENT OF HYPOXIA-RELATED DISEASES

1. A pharmaceutical composition, consisting of 1-10 ?M of N,N,N?,N?-tetrakis-(2-pyridylmethyl)-ethylenediamine (TPEN) or a pharmaceutically acceptable salt thereof, a 10-50 kDa alginate compound in an amount of 0.1 to about 1% (w/v), and a pharmaceutically acceptable carrier.
US Pat. No. 10,653,686

COMPOSITIONS AND METHODS FOR TREATMENT OF SYMPTOMS IN PARKINSON'S DISEASE PATIENTS

1. A pulsatile release dosage form for twice-daily administration, said form comprising a capsule comprising an effective amount of nicotine for treatment of symptoms of Parkinson's Disease or symptoms associated with dopaminergic treatment of Parkinson's Disease, wherein said capsule is configured to exhibit pulsatile release of said nicotine when administered, the pulsatile release comprising a first peak and a second peak, wherein the first peak occurs within about two hours of administration and the second peak occurs between about two hours and about twelve hours after administration, wherein said capsule comprises a powder comprising nicotine for providing the first release peak upon administration to a patient, and a bead comprising nicotine for providing the second release peak.
US Pat. No. 10,654,966

LOW-VISCOSITY PHOSPHATE POLYOLS

1. A phosphate polyol formulation comprising:a polyester polyol;
a halogen-free phosphate polyol;
a blowing agent;
a catalyst;
a surfactant;
an aromatic isocyanate; and
a fire-retardant non-isocyanate-reactive compound,
wherein the fire-retardant non-isocyanate-reactive compound comprises a triethyl phosphate compound and
wherein a weight ratio of the halogen-free phosphate polyol to the triethyl phosphate compound is approximately 90:10.
US Pat. No. 10,657,271

VERIFICATION TECHNIQUES FOR ENHANCED SECURITY

International Business Ma...

1. A method of identity verification, the method comprising:positioning a lab-on-chip device within a predetermined range of a computing device;
off-gassing a volatile compound from the computing device to the lab-on-chip device, wherein the computing device is configured to control an off-gassing rate of the volatile compound;
verifying the computing device at the lab-on-chip device using the off-gassed volatile compound off-gassed from the computing device;
receiving an expected biological sample value at the computing device or the lab-on-chip device in response to the verification, wherein the expected biological sample value indicates an expected concentration of a material biologically processed by a courier;
determining, at the computing device, whether a measured biological sample value is associated with the courier based on a comparison of the expected biological sample value to the measured biological sample value; and
determining, at the computing device, a particular set of operations to be performed based on a result of the comparison.
US Pat. No. 10,653,687

METHODS AND PHARMACEUTICAL COMPOSTIONS FOR TREATING RHABDOMYOLYSIS

FONDATION IMAGINE, Paris...

1. A method for treating rhabdomyolysis in a subject in need thereof, comprising the step of administering to said subject a at least one compound selected from the group consisting of one or more TLR9 antagonists and one or more inhibitors of TLR9 expression.
US Pat. No. 10,654,968

METHOD OF FORMING AND USE OF A CROSSLINKED POLYMER

Sumitomo Chemical Company...

1. A method of forming a crosslinked polymer and an anion, the method comprising the step of reacting a first polymeric substituent comprising a nucleophilic group and a second polymeric substituent comprising an electrophilic group wherein the first polymeric substituent is a substituent of a first polymer and the second polymeric substituent is a substituent of the first polymer or a second polymer.
US Pat. No. 10,653,693

PRMT5 INHIBITORS AND USES THEREOF

Epizyme, Inc., Cambridge...

1. A method of treating colon cancer, the method comprising administering a PRMT5 inhibitor to a subject having colon cancer, wherein the colon cancer is p53-positive.
US Pat. No. 10,654,973

METHOD FOR PRODUCING POLYCARBONATE

Shell Oil Company, Houst...

1. A process for producing polycarbonate comprising contacting a dihydroxy capped carbonate and a diaryl carbonate in a reaction zone in the presence of a polymerization catalyst under polymerization conditions to produce polycarbonate, wherein the dihydroxy capped carbonate is a carbonate with a dihydroxy compound on each end, the dihydroxy capped carbonate is formed by the reaction of a dihydroxy compound with a dialkyl carbonate, and the dihydroxy compound is a dihydroxy aromatic compound.
US Pat. No. 10,654,974

BONE REPAIR MATERIAL OF MULTIVARIANT AMINO ACID POLYMER-HYDROXYAPATITE, SUPPORTIVE IMPLANTS AND THE PREPARATION METHOD THEREOF

SICHUAN NATIONAL NANO TEC...

1. A bone repair material, comprising a multivariant amino acid polymer having ?-aminocaproic acid, one or more ?-amino acids, and a modified hydroxyapatite,wherein the modified hydroxyapatite comprises a pharmaceutically acceptable calcium salt and hydroxyapatite,
wherein a mass ratio of the calcium salt to hydroxyapatite is 2:98 to 20:80,
wherein a mass percentage of the modified hydroxyapatite is 10-70% based on a total mass of the bone repair material, and
wherein a molar percentage of ?-aminocaproic acid in the multivariant amino acid polymer is 60-99% based on a total molar quantity of amino acids in the multivariant amino acid polymer.
US Pat. No. 10,653,695

PHARMACEUTICAL FORMULATIONS OF NEFLAMAPIMOD

EIP Pharma, LLC, Boston,...

1. A pharmaceutical composition suitable for oral administration, comprising:neflamapimod; and
lactose,
wherein the ratio (w/w) of lactose to neflamapimod is about 8:1.
US Pat. No. 10,654,975

TIRE

BRIDGESTONE CORPORATION, ...

1. A tire comprising a tire skeleton body that is made of a resin material containing a polyamide-based thermoplastic elastomer and has a ring shape, whereinthe polyamide-based thermoplastic elastomer includes a hard segment, a soft segment consisting of a constituent unit derived from polypropylene glycol, and a binding portion that binds two or more segments and that consists of a constituent unit derived from a dicarboxylic acid of from 6 to 20 carbons, the polyamide-based thermoplastic elastomer having a weight average molecular weight of from 20,000 to 250,000;
the tire skeleton body comprises (a) first and second bead parts, (b) first and second side parts, the first side part extending from the first bead part in the outward radial direction of the tire, and the second side part extending from the second bead part in the outward radial direction of the tire, and (c) an outer peripheral crown part connecting a first outward end of the first side part in the radial direction of the tire with a second outward end of the second side part in the radial direction of the tire, and
an annular bead core is embedded in each of the first and second bead parts.
US Pat. No. 10,655,232

ADDITIVES TO CONTROL HYDROGEN SULFIDE RELEASE OF SULFUR CONTAINING AND/OR PHOSPHORUS CONTAINING CORROSION INHIBITORS

Baker Hughes, a GE compan...

1. A treated system comprising:a system containing fluid selected from the group consisting of an aqueous system, an aerobic system, an anaerobic system, and combinations thereof; and
a corrosion inhibitor comprising (1) at least one phosphorous-containing compound selected from the group consisting of O,O-disubstituted dithiophosphoric acid, pyrophosphates, and combinations thereof and
(2) at least one additive selected from the group consisting of an aminal, a dialkylamine, and combinations thereof;
wherein the aminal has a formula of (R1)(R2)N—CH2—N(R3)(R4) where each of R1-R4 is an alkyl group, an aryl group, a substituted aryl group, and/or an alkylalkoxylate, and where R1, R2, R3, and R4 are the same or different.
US Pat. No. 10,653,697

COMPOSITIONS AND METHODS OF USE OF CIS-4-[2-{[3S,4R)-3-FLUOROOXAN-4-YL]AMINO}8-(2,4,6-TRICHLOROANILINO)-9H-PURIN-9-YL]-1-METHYLCYCLOHEXANE-1-CARBOXAMIDE

Celgene Corporation, Sum...

34. A method for treating a cancer, comprising administering to a subject in need thereof a tablet comprising 15-25% of cis-4-[2-{[(3S,4R)-3-fluorooxan-4-yl]amino}-8-(2,4,6-trichloroanilino)-9H-purin-9-yl]-1-methylcyclohexane-1-carboxamide or an isotopologue, pharmaceutically acceptable salt, tautomer, solvate, hydrate, co crystal, clathrate, or polymorph thereof by weight, 32-43% of microcrystalline cellulose by weight, 32-43% of mannitol by weight, 2-6% of croscarmellose sodium by weight, 0.3-0.7% of fumed silica by weight, and 0.5-1.5% magnesium stearate by weight.
US Pat. No. 10,654,721

GRAPHENE DISPERSION, PROCESS FOR PRODUCING SAME, PROCESS FOR PRODUCING PARTICLES OF GRAPHENE/ACTIVE MATERIAL COMPOSITE, AND PROCESS FOR PRODUCING ELECTRODE PASTE

TORAY INDUSTRIES, INC., ...

1. A graphene dispersion liquid comprising graphene dispersed in an organic solvent and meeting both Equations (1) and (2) given below wherein D is the median diameter (?m) of the graphene measured by the laser diffraction/scattering type particle size distribution measurement method and S is the average size (?m) in the planar direction of the graphene calculated from the arithmetic mean of the longest diameter and shortest diameter of the graphene observed by a laser microscope:0.5 ?m?S?15 ?m   (1)
1.0?D/S?3.0  (2).
US Pat. No. 10,653,698

METHODS OF IMPROVING MYOCARDIAL PERFORMANCE IN FONTAN PATIENTS USING UDENAFIL COMPOSITIONS

Mezzion Pharma Co., Ltd.,...

1. A method of treating a patient born with functional single ventricle congenital heart disease who has undergone Fontan palliation for improving the patient's exercise capacity or for increasing the likelihood of improving the patient's exercise capacity, whose exercise capacity is adversely affected due to a decline in the patient's heart function after Fontan palliation, wherein the patient is in need of treatment to improve the patient's exercise capacity or to increase the likelihood of improving the patient's exercise capacity, wherein exercise capacity is determined by maximum oxygen uptake at maximum exercise output (VO2 measurement), said method comprising:orally administering to the patient in accordance with a treatment regimen an oral dosage form comprising an effective dose of udenafil, or a pharmaceutically acceptable salt thereof, to improve the patient's VO2 measurement or to increase the likelihood of improving the patient's VO2 measurement for improving the patient's exercise capacity or for increasing the likelihood of improving the patient's exercise capacity,
wherein the patient is a human,
wherein the patient has undergone Fontan surgery,
wherein the human patient is between about 12 years old and about 18 years old,
wherein the effective dose of udenafil, or a pharmaceutically acceptable salt thereof, is about 87.5 mg, and
wherein the treatment regimen comprises orally administering the oral dosage form to the human adolescent twice daily.
US Pat. No. 10,654,722

PREPARATION OF POLYMERIC RESINS AND CARBON MATERIALS

Georgia-Pacific Chemicals...

1. Carbon particles comprising a mean particle diameter of at least 1 mm and a span of 3 or less, wherein the span is equal to (Dv,90?Dv,10)/Dv,50, wherein the Dv,10, the Dv,50, and the Dv,90 are the volume particle sizes measured at 10%, 50% and 90%, respectively, of the particle size distribution, wherein greater than 75% of the carbon particles have a spherical geometry as determined by optical microscopy and image analysis, and wherein the carbon particles have a total specific surface area of about 1,500 m2/g to 1,900 m2/g.
US Pat. No. 10,654,978

TIRE

BRIDGESTONE CORPORATION, ...

1. A tire comprising a tire frame that is formed of a resin material and has a circular form,the resin material comprising a thermoplastic elastomer having a hard segment and a soft segment, and a polymer compound that has the same structural unit as the structural unit of the soft segment and which is different from the thermoplastic elastomer, and
the content of the polymer compound in the tire frame being from 0.20 parts by mass to 2.5 parts by mass with respect to 100 parts by mass of the thermoplastic elastomer contained in the tire frame, wherein the thermoplastic elastomer comprises at least one selected from the group consisting of a polyamide-based thermoplastic elastomer, a polyester-based thermoplastic elastomer, and a polyurethane-based thermoplastic elastomer.
US Pat. No. 10,656,515

PHOTOCHROMIC METAL ORGANIC FRAMEWORKS FOR INKLESS AND ERASABLE PRINTING

1. A porous metal organic framework (MOF) comprising:BINDI (N,N?-bis(5-isophthalic acid) naphthalenediimide), and
a metal ion selected from Mg and Sr,
wherein the metal ion is in coordination with the four carboxylate groups of BINDI, and
wherein said metal organic framework is useful for process for inkless and erasable printing.
US Pat. No. 10,653,700

COMPOSITION COMPRISING A THERAPEUTIC AGENT AND A RESPIRATORY STIMULANT AND METHODS FOR THE USE THEREOF

1. A method for treating opioid abuse comprising administering a pharmaceutical composition comprising oxycodone for the treatment of pain and doxapram to a patient orally in a single dosage form, wherein the ratio of the amount of oxycodone to the amount of doxapram ranges from 1:100 w/w to 100:1 w/w.
US Pat. No. 10,654,980

SILICONE RUBBER COMPOSITION, METHOD OF PRODUCING THE SAME, AND SILICONE RUBBER EXTRUDATE

MOMENTIVE PERFORMANCE MAT...

1. A silicone rubber composition comprising:(A) a 100 part by mass base polymer consisting of the following (A1) and (A2), with a ratio of the (A1) being 20 to 100% by mass to the whole (A), the base polymer having a viscosity of 5 to 20000 Pas at 25° C. and having an alkenyl group content of 0.001 to 0.3 mmol/g,
(A1) a polyorganosiloxane diol represented by the following formula (1), whose viscosity at 25° C. is 1 to 100 Pas
HO[(R12)SiO]n1[R1R2SiO]n2H  (1)where in the formula (1), each R1 independently represents a monovalent unsubstituted or substituted hydrocarbon group not containing an alkenyl group, and R2 represents an alkenyl group, and n1 and n2 each represent the total number of randomly polymerized or block-polymerized repeating units, n1 being an integer of 200 to 1200 and n2 being an integer of 0 to 30, and(A2) a polyorganosiloxane represented by the following average composition formula (2), whose viscosity at 25° C. is 0.2 to 40000 Pas
R3aSiO(4-a)/2  (2)where in the formula (2), each R3 independently represents a monovalent unsubstituted or substituted, saturated or unsaturated hydrocarbon group not containing a hydroxy group, and “a” represents a number in a range of 1.98 to 2.02;(B) a 10 to 50 part by mass silica powder whose specific surface area is 50 to 400 m2/g;
(C) a 1 to 10 part by mass organosilazane; and
(D) a catalytic amount of a peroxide compound as a curing agent.
US Pat. No. 10,656,516

PHOTOMASK BLANK, AND PREPARATION METHOD THEREOF

SHIN-ETSU CHEMICAL CO., L...

1. A photomask blank comprising a transparent substrate, at least one film (A) containing chromium and free of silicon, and at least one film (B) containing silicon, and oxygen or oxygen and nitrogen, and free of a transition metal, the film (A) and film (B) being contacted to each other, whereinthe photomask blank satisfies the following formula:
IA/IB<1,
where IA represents an intensity of secondary ions derived from Cr2O5 and Is represents an intensity of secondary ions derived from Cr at a position at which a maximum intensity of secondary ions derived from SiCrO5 is observed by measuring intensities of the secondary ions at an interface or its vicinity of the film (A) and film (B) along a thickness direction of the films with a time-of-flight secondary ion mass spectrometry (TOF-SIMS), and
the photomask blank is prepared by a method comprising steps of:
when the film (B) is deposited on the film (A), in a definite period of time at the initial stage of the deposition, sputtering the film (B) with supplying an oxygen-containing gas in an amount or flow rate reduced from the setting value conforming to the prescribed composition in accordance with function of the film (B) or without supplying an oxygen-containing gas, then, sputtering the film (B) with supplying an oxygen-containing gas in an amount or flow rate of the setting value conforming to the prescribed composition; or
when the film (A) is deposited on the film (B), sputtering the film (B) with supplying an oxygen-containing gas in an amount or flow rate of the setting value conforming to the prescribed composition in accordance with function of the film (B), then, in a definite period of time at the final stage of the deposition, sputtering the film (B) with supplying an oxygen-containing gas in an amount or flow rate reduced from the setting value conforming to the prescribed composition or without supplying an oxygen-containing gas.
US Pat. No. 10,653,701

SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY

NEUPHARMA, INC., Foster ...

1. A method of treating cancer in a patient, wherein said patient has one or more mutations in the EGFR gene, comprising administering to said patient a therapeutically effective amount of a substituted quinazoline compound comprising an electrophilic group capable of forming a covalent bond with a nucleophile, or a pharmaceutically acceptable salt thereof; wherein the cancer is skin cancer or lung cancer.
US Pat. No. 10,654,981

REINFORCED THERMOPLASTIC RESIN COMPOSITION AND MOLDED ARTICLE THEREOF

UMG ABS, LTD., Tokyo (JP...

1. A reinforced thermoplastic resin composition comprising:a resin main component (C) including 80% to 100% by mass of a polycarbonate resin (A), and 0% to 20% by mass of a graft copolymer (G) obtained by polymerizing a monomer mixture (m1) containing an aromatic alkenyl compound and a vinyl cyanide compound in a presence of a rubbery polymer (G1) (herein, the total of the polycarbonate resin (A) and the graft copolymer (G) is 100% by mass of the total mass of the resin main component (C));
a polyethylene terephthalate resin (B);
an inorganic filler (D); and
a glycidyl ether unit-containing polymer (E), and satisfying following requirements (a) to (c):
(a) the polyethylene terephthalate resin (B) is a solid phase polymerized material of recycled and/or repelletized polyethylene terephthalate resin, and a content of the polyethylene terephthalate resin (B) is 5 to 20 parts by mass with respect to 100 parts by mass of the resin main component (C),
(b) a content of the inorganic filler (D) is 20% to 50% by mass in 100% by mass of the reinforced thermoplastic resin composition, and
(c) the glycidyl ether unit-containing polymer (E) has a mass average molecular weight of 3,800 to 60,000, and a content of the glycidyl ether unit-containing polymer (E) is 1 to 10 parts by mass with respect to 100 parts by mass of the resin main component (C).
US Pat. No. 10,653,702

USE OF METAL-ORGANIC FRAMEWORK AS TUMOR ANGIOGENESIS INHIBITOR

Yunnan University, Kunmi...

1. A method for inhibiting tumor angiogenesis comprising administering to a subject in need thereof an effective amount of a metal-organic framework comprising Fe and ligand, wherein the ligand is terephthalic acid; and, wherein the tumor is lung cancer or ovarian cancer, andthe method does not comprise administering an additional anti-tumor agent to the subject simultaneously with the metal-organic framework.
US Pat. No. 10,654,982

METHOD FOR PREPARING POLARIZER PROTECTING FILM

LG CHEM, LTD., Seoul (KR...

1. A method for preparing a polarizer protecting film, comprising the steps of:stretching an unstretched polymeric film in a first direction that is a length direction or a width direction to prepare a uniaxially stretched polymeric film;
coating a cationic curable coating composition comprising an alicyclic epoxy-based compound and a cationic polymerization initiator onto at least one surface of the uniaxially stretched polymeric film, wherein the weight average molecular weight of the alicyclic epoxy-based compound is 100 to 5,000 g/mol;
stretching the uniaxially stretched polymeric film onto which the coating composition has been coated in a direction perpendicular to the first direction to form a biaxially stretched polymeric film; and
photo-curing the coating composition to yield a polarizer protecting film having formed thereon a stretched coating layer having a pencil hardness of H or higher.
US Pat. No. 10,653,703

COMPOSITIONS COMPRISING OMEGA-3 FATTY ACIDS, 17-HDHA AND 18-HEPE AND METHODS OF USING SAME

Solutex NA LLC, Miami, F...

1. A composition comprising:omega-3 fatty acids present in an amount of about 20% to about 95%, by weight, of the composition; and
17-hydroxy-4Z,7Z,10Z,13Z,15E,19Z-docosahexaenoic acid (“17-HDHA”), 14-hydroxy-4Z,7Z,10Z,12E,16Z,19Z-docosahexaenoic acid (“14-HDHA”), and 18-hydroxy-5Z,8Z,11Z,14Z,16E-eicosapentaenoic acid (“18-HEPE”), wherein the 18-HEPE is present in an amount of 0.02% to about 1%, by weight, of the composition.
US Pat. No. 10,656,519

RESIST STRIPPER AND RESIST STRIPPING METHOD

Nagase ChemteX Corporatio...

1. A resist stripper, comprising:(A) an amine;
(B) an organic solvent; and
(C) 0.0025 wt % or more and 1.5 wt % or less of a polyanilinesulfonic acid having a weight average molecular weight of 5,000 to 1,000,000 or a salt thereof.
US Pat. No. 10,653,704

INHALABLE FORMULATION

1. A process for preparing an inhalable active pharmaceutical ingredient comprising the steps of:simultaneously heating and agitating a suspension of an active pharmaceutical ingredient in a liquefied propellant in a vessel, wherein the heating is performed at a temperature of 30-50° C. for 6 hours to 5 days,
evaporating the propellant, and
collecting the resultant powder,
wherein the active pharmaceutical ingredient has a first amorphous content prior to the simultaneous heating and agitating step, and the resultant powder comprises the active pharmaceutical ingredient having a second amorphous content that is lower than the first amorphous content, and
wherein the inhalable active pharmaceutical ingredient is one or more of fluticasone proprionate, fluticasone furoate, budesonide, beclomethasone diproprionate, and mometasone furoate.
US Pat. No. 10,654,984

HETEROGENEOUS FOAM COMPOSITION AND METHOD

SEKISUI VOLTEK, LLC, Col...

1. A process comprising:freely placing a first foamable material inside of a first region of a mold space,
freely placing a second foamable material inside of a second region of the mold space, the first foamable material and the second foamable material comprising a physical, chemical, or quantitative difference, or any combination thereof; and
concurrently foaming both the first and the second foamable materials inside of the mold space to produce a heterogeneous foam comprising a first portion that differs from the second portion, wherein at least one of the first and the second foamable materials comprises foamable particles.
US Pat. No. 10,656,521

PHOTOSENSITIVE RESIN COMPOSITION, PHOTOSENSITIVE ELEMENT, CURED PRODUCT, SEMICONDUCTOR DEVICE, METHOD FOR FORMING RESIST PATTERN, AND METHOD FOR PRODUCING CIRCUIT SUBSTRATE

HITACHI CHEMICAL COMPANY,...

9. A method for forming a resist pattern, comprising:a step of forming a photosensitive layer comprising the photosensitive resin composition according to claim 1 on a substrate;
an exposing step of exposing the photosensitive layer in order to form a predetermined pattern;
a developing step of developing the photosensitive layer after the exposing step to obtain a resin pattern; and
a heat-treating step of heat-treating the resin pattern.
US Pat. No. 10,653,706

HIGH-STRENGTH TESTOSTERONE UNDECANOATE COMPOSITIONS

Lipocine Inc., Salt Lake...

1. A method for replacement therapy in a male having a condition associated with a deficiency or absence of endogenous testosterone said method comprising:orally administering to a male identified as having a morning serum testosterone level of less than 300 ng/dL a daily dosing regimen of a pharmaceutical composition comprising about 14 weight % (wt %) to about 35 wt % testosterone undecanoate and a carrier comprising oleic acid, polyoxyl 40 hydrogenated castor oil, and borage seed oil, that provides about 480 mg testosterone undecanoate to said male per day; and
orally administering to the male, following a determination of the male's serum testosterone level at from 1-8 hours after a single dosage of the pharmaceutical composition at steady state during the daily dosing regimen, a daily dosing regimen of a pharmaceutical composition comprising about 14 wt % to about 35 wt % testosterone undecanoate and a carrier comprising oleic acid, polyoxyl 40 hydrogenated castor oil, and borage seed oil, that provides within plus 40% of about 480 mg of testosterone undecanoate to said male per day when the serum testosterone level determined indicates said male needs a dosage increase, to provide a serum testosterone Cave in said male in the range of from about 300-1100 ng/dL.
US Pat. No. 10,654,986

SURFACE TREATED FILLER MATERIAL PRODUCT FOR ALPHA-NUCLEATION OF POLYOLEFINS

Omya International AG, O...

1. A surface treated filler material product for alpha-nucleation of polyolefins, comprising(a) a calcium carbonate-comprising filler material, and
(b) a bicyclo[2.2.1]heptane-2,3-dicarboxylic acid and/or a monovalent salt of the bicyclo[2.2.1]heptane-2,3-dicarboxylic acid and/or a divalent salt of the bicyclo[2.2.1]heptane-2,3-dicarboxylic acid being present on at least a part of the accessible surface area of the calcium carbonate-comprising filler material,
wherein the amount of the bicyclo[2.2.1]heptane-2,3-dicarboxylic acid and/or the monovalent salt of the bicyclo[2.2.1]heptane-2,3-dicarboxylic acid and/or the divalent salt of the bicyclo[2.2.1]heptane-2,3-dicarboxylic acid, in mg, on the accessible surface area of the calcium carbonate-comprising filler material, in m2, is from 0.001 mg/m2 to 500 mg/m2.
US Pat. No. 10,653,707

TOPICAL MINOCYCLINE COMPOSITIONS AND METHODS OF USING THE SAME

Laboratory Skin Care, Inc...

1. A topical minocycline composition comprising ceramic porous calcium particles loaded with a minocycline active agent, wherein the composition is a formulation configured to be applied to a keratinized skin surface location of a mammal.
US Pat. No. 10,654,219

METHOD FOR MANUFACTURING A THREE-DIMENSIONAL OBJECT

The Procter and Gamble Co...

1. A method of manufacturing a three-dimensional water-soluble consumer product comprising an actual set of voxels, the method comprising the steps of:a. providing a digital description of the product as a set of voxels;
b. sequentially 3D printing, the actual set of voxels corresponding to the digital set of voxels;
wherein at least one voxel comprises:
from about 40 wt % to about 96 wt % of a water-soluble polymer composition comprising a molecular weight from about 1000 to about 95000 AMU;
wherein the water-soluble polymer is selected from the group consisting of nonionic PEG homopolymers, PEG copolymers, and mixtures thereof;
from about 1 wt % to about 65 wt % of a filler comprising a melt temperature greater than about 75° C. and wherein the filler is solid at a temperature greater than the melting and printing temperature of the at least one voxel;
wherein the filler comprises an organic material selected from the group consisting of starches, gums, proteins, amino acids, water soluble polymers, water degradable polymers, water insoluble polymers, sugars, sugar alcohols, surfactants, fatty amphiphiles and mixtures thereof;
wherein the filler further comprises a benefit agent selected from the group consisting of builders, surfactants, bleach activators, bleach catalysts, bleach boosters, bleaches, antibacterial agents, colorants, perfumes, pro-perfumes, composition malodor control and removal agents, odor neutralizers, polymeric dye transfer inhibiting agents, crystal growth inhibitors, photobleaches, heavy metal ion sequestrants, anti-tarnishing agents, anti-microbial agents, anti-oxidants, anti-redeposition agents, electrolytes, divalent or trivalent ions, metal ion salts, corrosion inhibitors, suds stabilizing polymers, solvents, process aids, dye fixatives, dye abrasion inhibitors, sunscreen agents, insect repellants, bittering agents, antiperspirant and mixtures thereof;
wherein the water-soluble consumer product is selected from the group consisting of conditioners, hair colorants, body wash, shampoo, facial wash, dish detergent, personal cleansing, skin care products, shaving products, fabric care products, hard surface cleansers, air care products, oral care products, over-the-counter health care products, and combinations thereof.
US Pat. No. 10,654,987

TITANIUM COMPLEXES AS VULCANIZATION CATALYSTS

1. A curable composition comprisinga) a polymer having at least one silicon-containing group of formula (1)
—Si(R1)k(Y)3-k   (1),
wherein
R1 is selected from a hydrocarbon radical containing 1 to 20 C atoms or a triorganosiloxane group of formula —O—Si(R2)3, where each R2 is independently selected from a hydrocarbon radical containing 1 to 20 C atoms;
each Y is independently selected from a hydroxy group or a hydrolyzable group; and
k is 0, 1, or 2;
b) at least one titanium complex of formula (2)
TiL(OR3)2  (2),
wherein
each R3 is independently selected from a C1-20 alkyl or aryl which may optionally contain one or more heteroatoms or silicon atoms; and
L is a deprotonated, tridentate ligand; and
c) optionally a compound which has a hydrolyzable silicon-containing group and a weight average molecular weight in the range of 100 to 1,000 g/mol measured by GPC according to DIN 55672-1:2007-08.
US Pat. No. 10,653,708

USES OF ETHER PHOSPHOLIPIDS IN TREATING DISEASES

Institute of Rheological ...

1. A method of treating the Alzheimer's disease, Parkinson disease, or obesity, comprising administering to a subject in need thereof a therapeutically effective amount of ether phospholipids or a composition containing ether phospholipids,wherein the ether phospholipids are derived from a method comprising:
(A) a step of extracting total lipids from bivalve tissue with a mixture of a non-polar organic solvent and a branched alcohol; and
(B) a step of reacting the total lipids obtained by the step (A) with phospholipase A1 to hydrolyze diacyl phospholipids mixed therein, followed by solvent partition to get a purified ether phospholipids, and
wherein the therapeutically effective amount of the ether phospholipids is about 0.5 mg to about 20 mg per dosage.
US Pat. No. 10,656,269

ADJACENT VEHICLE DETECTION DEVICE

SOKEN, INC., Nisshin, Ai...

1. An apparatus for a vehicle, comprising:a first distance sensor that is mounted on the vehicle and that detects a distance to an object which exists in a first detection area around the vehicle, the first distance sensor being an ultrasonic sensor,
wherein:
the first distance sensor detects the object by comparing an intensity of a signal detected by the first distance sensor with a threshold that is set based on a velocity of the vehicle;
the threshold being set to a first value when the velocity of the vehicle is greater than a reference vehicle velocity and being set to a second value when the velocity of the vehicle is lower than the reference vehicle velocity, the first value being less than the second value.
US Pat. No. 10,655,246

METHOD FOR PRODUCING SINGLE-HOLE ULTRA SOFT YARNS

LOFTEX USA LLC, New York...

1. A method of producing soft yarns, comprising the steps of:receiving from a first pre-drawing machine a plurality of finish fibers;
receiving from a second pre-drawing machine a water soluble fiber;
providing a multi-hole drawing tool, the multi-hole drawing tool having a center passage disposed therethrough configured to allow the passage of the water soluble fiber and at least two finish fibers passages disposed therethrough and configured to allow passage of the one of the at least two finish fibers of the plurality of finish fibers in each respective finish fiber passage;
producing a combined fiber by:
drawing each of the received plurality of finish fibers through a respective one of the at least two finish fibers passages and the received water soluble fiber through the center passage such that the at least two finish passages are arranged around the water soluble fiber passage to form the combined fiber; and
providing the combined fiber to a speed frame.
US Pat. No. 10,655,247

METHOD FOR PRODUCING MULTI-HOLE ULTRA SOFT YARNS

LOFTEX USA LLC, New York...

1. A method of producing soft yarns, comprising the steps of:receiving from a first pre-drawing machine a plurality of finish fibers;
receiving from a second pre-drawing machine a water soluble fiber;
providing a first multi-hole drawing tool, the multi-hole drawing tool having a first planar surface and a second planar surface and a center passage disposed therethrough and configured to allow the passage of the water soluble fiber from the first planar surface to the second planar surface, and at least two finish fibers passages at a distance from the center passage and disposed the first and second planar surfaces and configured to allow passage of one of the at least two finish fibers of the plurality of finish fibers in each respective finish fiber passage;
producing, prior to a speed frame process, a combined fiber by:
introducing the plurality of finish fibers and the water soluble fiber into respective holes of the multi-hole drawing tool with the finish fibers arranged around the water soluble fiber;
pulling the finish fibers and the water soluble fiber through the multi-hole drawing tool to form a combined fiber, wherein the blend ratio of the combined fiber is about 5% water soluble fiber;
the combined fiber having the water soluble fiber surrounded by the finish fiber; and
roving the combined fiber.
US Pat. No. 10,653,712

HIGH PURITY RNA COMPOSITIONS AND METHODS FOR PREPARATION THEREOF

ModernaTX, Inc., Cambrid...

1. A method of producing messenger RNA that comprises an open reading frame, the method comprising:(a) forming a reaction mixture comprising a DNA template and nucleoside triphosphates (NTPs) including adenosine triphosphate (ATP), cytidine triphosphate (CTP), uridine triphosphate (UTP), guanosine triphosphate (GTP), or an analog of each respective nucleoside, and a buffer; and
(b) incubating the reaction mixture to produce a composition comprising messenger RNA,
wherein the ratio of concentration of GTP to concentration of ATP is at least 2:1, the ratio of concentration of GTP to concentration of CTP is at least 2:1, and the ratio of concentration of GTP to concentration of UTP is at least 2:1.
US Pat. No. 10,654,992

RUBBER COMPOSITION COMPRISING SILICONE OIL

COMPAGNIE GENERALE DES ES...

1. A tread for a pneumatic tire comprising a rubber composition comprising at least:a diene elastomer;
at least 60 phr of silica;
20 to 100 phr of a plasticizer comprising more than 4 phr of a mercapto-modified silicone oil; and
0.2 and 20 phr of carbon black,
wherein the diene elastomer is chosen from the group consisting of natural rubber, synthetic polyisoprenes, polybutadienes, butadiene copolymers, isoprene copolymers and mixtures thereof, and
wherein the plasticizer further comprises a compound selected from the group consisting of hydrocarbon resins, liquid plasticizers other than the mercapto-modified silicone oil, and mixtures thereof.
US Pat. No. 10,654,993

RUBBER COMPOSITION CONTAINING A BLEND OF SILICAS AND RELATED PROCESSES FOR IMPROVING WEAR

Bridgestone Americas Tire...

1. A rubber composition comprising:a. natural rubber, polyisoprene, or a combination thereof;
b. at least one conjugated diene monomer containing polymer or copolymer;
c. a first silica filler having a BET surface area of at least 220 m2/g;
d. a second silica filler having a BET surface area lower than that of the first silica filler and greater than 145 m2/g;
e. optionally carbon black filler;
wherein the total amount of first silica filler and second silica filler comprises at least 20 phr, and the first and second silica fillers are present in relative amounts by weight of 30:70 to 70:30, respectively, and
the total amount of (a) and (b) is 100 parts with (a) comprising at least 25% by weight of those 100 parts.
US Pat. No. 10,653,714

COMPOSITION AND METHOD TO ENHANCE EXPRESSION OF HUMAN DEFENSIN 2

The Cleveland Clinic Foun...

1. A method of enhancing the expression of human beta defensin 2 (HBD2) in a human patient's colon epithelium cells, said method comprising the step oforally administering a pharmaceutical composition to said patient, wherein said composition comprises hyaluronan and a pharmaceutically acceptable carrier, and said hyaluronan component consists of hyaluronan fragments having a molecular weight of about 35 kDa.
US Pat. No. 10,654,994

STYRENE-BUTADIENE RUBBER COMPOUND AND RUBBER COMPOSITION FOR TIRE BEAD FILLERS COMPRISING THE SAME

LG Chem, Ltd., (KR)

1. A styrene-butadiene rubber compound comprising:a) a first styrene-butadiene rubber having a styrene content of 60 to 95% by weight, a particle size of 100 to 200 nm, and a Mooney viscosity difference (?MV) of 3 to 7 before/after blending; and
b) a second styrene-butadiene rubber having a styrene content of 5 to 10% by weight.
US Pat. No. 10,658,068

EVOLUTIONARY MODELS OF MULTIPLE SEQUENCE ALIGNMENTS TO PREDICT OFFSPRING FITNESS PRIOR TO CONCEPTION

Ancestry.com DNA, LLC, L...

1. A computer-implemented method for predicting variants being deleterious in virtual progenies, a deleterious variant associated with disease or reduced likelihood of surviving or reproducing, the method comprising:retrieving, from a computer memory, multiple aligned genetic sequences representing genetic material obtained from DNA samples of multiple organisms of one or more different species, the aligned genetic sequences aligning genetic sequences of the multiple organisms at one or more genetic loci;
generating a plurality of virtual progenies of two potential parents by combining at least a portion of genetic information representing genetic material obtained from biological samples of the two potential parents, the generating of the virtual progenies comprising:
(i) retrieving, for each parent, a diploid genetic sequence comprising two alleles at each genetic locus,
(ii) selecting, for each parent, one of the two alleles for each genetic locus, the selection progressing locus-by-locus along the diploid genetic sequence and based at least partially on a stochastic process,
(iii) forming a haploid genetic sequence based on the selected alleles for each parent, the haploid genetic sequence representing a genetic sequence of a virtual gamete,
(iv) combining the haploid genetic sequences of the two parents to form a virtual progeny diploid genetic sequence associated with a virtual progeny, and
(v) repeating at least steps (ii) to (iv) multiple times to generate the plurality of virtual progenies of the two potential parents;
aligning the plurality of virtual progenies with the multiple sequence alignment of the multiple organisms;
retrieving a machine learning computer model that is trained based on at least the aligned genetic sequences of the multiple organisms, the machine learning computing model comprises a phylogenetic tree generated from the multiple aligned genetic sequences, the phylogenetic tree modeling evolutionary variations of allele variants, each evolutionary variation of an allele variant corresponding to a prediction of a likelihood that the allele variant would be deleterious;
inputting aligned sequences of the plurality of virtual progenies to the machine learning computer model to compute one or more likelihoods that a particular allele variant in the plurality of virtual progenies will be deleterious based on the evolutionary variation of the particular allele variant of the plurality of virtual progenies aligned with the multiple sequence alignment of the multiple organisms, the one or more likelihoods computed based on a frequency with which the particular allele variant has occurred and persisted in the multiple organisms according to the phylogenetic tree.
US Pat. No. 10,653,715

METHODS AND COMPOSITIONS FOR EXTENDING LIFESPAN

Longevica Theraputics Inc...

1. A method of prolonging the lifespan of a subject, the method comprising administering to the subject an effective amount of:(a) one or more compounds selected from: (i) clofibrate, and (ii) inulin; and
(b) diethylenetriaminepentaacetic acid (DTPA)wherein the lifespan to the subject is prolonged relative to the lifespan of the subject in the absence of the administration.
US Pat. No. 10,654,995

PNEUMATIC TIRE

1. A pneumatic tire comprising a tread, the tread comprising a rubber composition comprising from 30 to 80 phr of a styrene-butadiene rubber having a Tg ranging from ?70° C. to ?40° C., from 10 to 50 phr of a high vinyl polybutadiene having a Tg ranging from ?40° C. to ?5° C. and has an isomeric vinyl 1,2 content in a range of from 50 to 90 percent by weight, and from 10 to 30 phr of a natural rubber or synthetic polyisoprene, silica, a blocked mercaptosilane, a traction resin, and from 3 to 30 phr of a low molecular weight polybutadiene functionalized with a hydroxyl functional group and having a molecular weight Mw ranging from 1,000 to 25,000 g/mol and a Tg ranging from ?50° C. to ?20° C.
US Pat. No. 10,658,069

BIOLOGICAL SEQUENCE VARIANT CHARACTERIZATION

International Business Ma...

1. An article of manufacture comprising a computer readable storage medium for storing computer readable program code which, when executed, causes a computer node to perform the steps of:receiving source biological sequence data comprising a collection of source sequences derived from an unknown biological sample, wherein the collection of source sequences derived from the unknown biological sample comprises a plurality of overlapping sequence reads providing greater than two times coverage of each of a plurality of bases of at least one genome in the source biological sequence data;
extracting short fixed length sub-sequences, defined as reference sub-sequences, from a collection of reference sequences derived from a reference biological sample;
constructing an index showing which short fixed length reference sub-sequence occurs in which reference sequences of the reference biological sample;
extracting short fixed length sub-sequences, the same length as the reference sub-sequences and defined as source sub-sequences, from the collection of source sequences derived from the unknown biological sample;
compiling the short fixed length source sub-sequences to determine the frequency of each within the collection of source sequences derived from the unknown biological sample;
selecting at least a subset of the short fixed length source sub-sequences based at least in part on comparing (i) the determined frequency of the short fixed length source sub-sequences within the collection of source sequences derived from the unknown biological sample with (ii) matching short fixed length reference sub-sequences in the index of references sequences of the reference biological sample;
performing a targeted assembly of the source biological sequence data by:
generating an overlap graph utilizing the selected subset of the short fixed length source sub-sequences; and
identifying at least one path from at least a first one of the reference sub-sequences corresponding to an initial position of at least one designated biological sequence variant to at least a second one of the reference sub-sequences corresponding to a terminal position of said at least one designated biological sequence variant; and
determining that the unknown biological sample comprises said at least one designated biological sequence variant responsive to identifying said at least one path.
US Pat. No. 10,653,716

INJECTABLE MONOPHASE HYDROGELS

ALLERGAN INDUSTRIE, SAS, ...

1. An injectable composition comprising a hyaluronic acid gel, the hyaluronic acid gel comprising:about 5% by weight to about 50% by weight of a first hyaluronic acid having a molecular weight of about 3×106 Da; and
about 50% by weight to about 95% by weight of a second hyaluronic acid having a molecular weight of about 3×105 Da;
wherein the hyaluronic acid gel is crosslinked via covalent bonding between a bifunctional crosslinker and hydroxyl moieties of the first and second hyaluronic acids; and further wherein the hyaluronic acid gel has a Tan ? 1 Hz in the range of about 0.07 to about 0.12.
US Pat. No. 10,654,996

METHODS OF CROSSLINKING AND COMPOSITIONS

Equistar Chemicals, LP, ...

1. A method for crosslinking a first polyolefin comprising the steps of:(A) selecting a second polyolefin being substantially-miscible with the first polyolefin and having particles of a morphology selected from the group consisting of powder and substantially spherical;
(B) admixing the second polyolefin to the first polyolefin;
(C) adding about 0.1 to about 10 wt. % of a silane-crosslinking agent to the second polyolefin, thereby producing a substantially-miscible, polyolefin-based, silane-crosslinking-agent carrier;
(D) melt blending the first polyolefin and the substantially-miscible, polyolefin-based, silane-crosslinking-agent carrier, thereby yielding a moisture-crosslinkable polyolefin-based composition; and
(E) crosslinking the moisture-crosslinkable polyolefin-based composition.
US Pat. No. 10,658,070

RESOLVING GENOME FRACTIONS USING POLYMORPHISM COUNTS

Verinata Health, Inc., S...

1. A method, implemented using a computer system that includes one or more processors and system memory, of estimating a fraction of fetal DNA in DNA obtained from a bodily fluid of a pregnant individual carrying a fetus, the method comprising:(a) sequencing the DNA obtained from the bodily fluid of the pregnant individual using a nucleic acid sequencer under conditions that produce DNA sequence reads;
(b) aligning or otherwise mapping, by the computer system, the DNA sequence reads to a reference genome comprising a plurality of polymorphism sites for a plurality of designated polymorphisms;
(c) determining, by the computer system, allele frequencies of the mapped DNA sequence reads for the plurality of designated polymorphisms;
(d) classifying, by the computer system, the plurality of designated polymorphisms based on a combination of the zygosity of the pregnant individual and the zygosity of the fetus; and
(e) estimating, by the computer system, the fraction of fetal DNA in the DNA obtained from the pregnant individual using the allele frequencies determined in (c) in conjunction with the classification of zygosities from (d),
wherein steps (b)-(e) are performed based on the plurality of polymorphisms,
wherein the classifying in (d) classifies the plurality of designated polymorphisms into the following combinations: (i) the pregnant individual is homozygous and the fetus is homozygous, (ii) the pregnant individual is homozygous and the fetus is heterozygous, (iii) the pregnant individual is heterozygous and the fetus is homozygous, and (iv) the pregnant individual is heterozygous and the fetus is heterozygous, and
wherein (e) comprises using allele frequencies of polymorphisms of two or more of combinations (i)-(iv) to estimate the fraction of fetal DNA.
US Pat. No. 10,654,997

BUFFER TUBES FOR FIBER OPTIC CABLES

Dow Global Technologies L...

1. A composition comprising in weight percent (wt %) based on the weight of the composition:(A) 15-70 wt % polypropylene (PP),
(B) 15-70 wt % high density polyethylene (HDPE),
(C) >0-30 wt % propylene-ethylene copolymer (PE copolymer),
(D) 2-15 wt % olefin block composite, and
(E) 0-20 wt % of one or more of a nucleating agent, filler and additive, with the proviso that the weight ratio of PP to HDPE is greater than (>) 1.
US Pat. No. 10,653,718

COMPOSITION FOR THE ORAL ADMINISTRATION OF MAGNESIUM, IN ASSOCIATION WITH A COMPOSITION FOR TREATING TYPE 2 DIABETES OR THE COMPLICATIONS THEREOF

anda protective coating which slows down the dissolution of the magnesium at the gastric level.
US Pat. No. 10,654,998

MOULDING COMPOSITION

SABIC GLOBAL TECHNOLOGIES...

1. A moulding composition comprising polypropylene, inorganic filler and mould release composition, wherein the mould release composition is from 0.1-2.0 wt. %, based on the weight of the moulding composition and comprises maleic anhydride modified polypropylene and glycol or glycerol ester of a fatty acid, wherein the inorganic filler is selected from calcium carbonate, talc or mixture of calcium carbonate and talc, and wherein the amount of maleic anhydride modified polypropylene is from 0.05-0.9 wt. % based on the weight of the moulding composition.
US Pat. No. 10,654,999

FILM COMPRISING A POLYOLEFIN COMPOSITION

Basell Poliolefine Italia...

1. A film comprising:a polyolefin composition comprising:
A) 5-30% by weight, based upon the total weight of the polyolefin composition, of a propylene homopolymer containing 5% by weight or less of a fraction soluble in xylene at 25° C. (XSA), or a propylene ethylene copolymer containing 90% by weight or more of propylene units; containing 10% by weight or less of a fraction soluble in xylene at 25° C. (XSA), both the amount of propylene units and of the fraction XSA being referred to the weight of A);
B) 20-50% by weight, based upon the total weight of the polyolefin composition; of a copolymer of ethylene and a C3-C8 alpha-olefin containing from 0.1% to 20% by weight of alpha-olefin units and containing 25% by weight or less of a fraction soluble in xylene at 25° C. (XSB), both the amount of alpha-olefin units and of the fraction XSB being referred to the weight of (B); and
C) 30-60% by weight, based upon the total weight of the polyolefin composition, of a copolymer of ethylene and propylene containing from 25% to 75% by weight of ethylene units and containing from 40% to 95% by weight of a fraction soluble in xylene at 25° C. (XSC), both the amount of ethylene units and of the fraction XSC being referred to the weight of (C),
wherein the amounts of (A), (B) and (C) being referred to the total weight of (A)+(B)+(C) and the sum of the amount of (A)+(B)+(C) being 100.
US Pat. No. 10,656,535

METROLOGY METHOD FOR A SEMICONDUCTOR MANUFACTURING PROCESS

IMEC VZW, Leuven (BE)

1. A method for monitoring critical dimensions of 1-dimensional features or 2-dimensional features arranged in a pattern and produced on a substrate by a process step that is part of or related to a manufacturing process for producing a semiconductor device,wherein the process step is performed in accordance with a predefined pattern design,
wherein one or more metrology targets are added to the predefined pattern design,
wherein each metrology target comprises one or more marks of an asymmetric design,
wherein each mark of the asymmetric design comprises a uniform portion of width K and a periodic portion of width L arranged adjacently in a given direction,
wherein the periodic portion comprises 1-dimensional features or 2-dimensional features arranged in a regular array,
wherein the periodic portion comprises an array of 1-dimensional features or 2-dimensional features at a design pitch,
wherein the design dimension of the 1-dimensional features or one of the design dimensions of the 2-dimensional features is equal to or situated in a range around a nominal value w0, and
wherein the method comprises each of the following steps performed in relation to each of the one or more metrology targets:
performing the process step, thereby obtaining one or more asymmetric mark patterns corresponding respectively to the one or more marks of the asymmetric design;
defining a parameter S representative of a position of a centroid of the one or more asymmetric mark patterns, wherein the parameter S changes essentially linearly as a function of at least one of the design dimensions of the 1-dimensional or 2-dimensional features;
determining, from the one or more asymmetric mark patterns, a shift ?S of the parameter S for an asymmetric mark having features of design dimension w0 with respect to a reference value for the parameter S, wherein the reference value is valid at a previously defined process operating point for the process step; and
assessing, based on the shift ?S, a critical dimension of 1-dimensional or 2-dimensional features of the one or more asymmetric mark patterns produced by the process step.
US Pat. No. 10,658,073

METHODS AND SYSTEMS FOR INTERPRETATION AND REPORTING OF SEQUENCE-BASED GENETIC TESTS USING POOLED ALLELE STATISTICS

QIAGEN Redwood City, Inc....

1. A method for building a community database of variant observations, comprising:receiving human variant datasets derived from samples generated by a plurality of distinct users, wherein the users consented to share pooled variant observations with other users;
storing the received human variant datasets in a knowledge base of genomic information, wherein the knowledge base comprises an ontology data structure that identifies a causal relationship between a genetic variant and a phenotype based on a combination of the genetic variant and modifier variant information, wherein the knowledge base links the genetic variant and the modifier variant information, wherein the modifier variant information is based on curated evidence and derived from patient test information, and wherein the modifier variant information identifies whether modifier variants that modify a severity of the phenotype are likely to exist;
searching the knowledge base to identify a plurality of variant observations that meet inclusion criteria for a pool;
adding each identified variant observation to the pool;
calculating one or more anonymized allele statistics from the pool; and
classifying a variant observation in the pool into a clinical significance category using the knowledge base and the anonymized allele statistics of the pool,
wherein at least one of the receiving, storing, searching, adding, calculating, or classifying are performed by one or more computers.
US Pat. No. 10,653,720

PREVENTION OF PROTEIN GLYCATION USING LYSINE/ZINC SUPPLEMENTS

Lysulin, Inc., San Diego...

1. A method of monitoring blood sugar control, the method comprising:administering a supplement consisting of lysine and zinc to a user;
monitoring a concentration of glucose before and after the supplement is administered in a bio-sample; and
determining a change in a dose of the supplement based on the concentration of glucose found in the bio-sample.
US Pat. No. 10,654,744

GLASS

NIPPON ELECTRIC GLASS CO....

1. A glass, comprising as a glass composition, in terms of mol %, 60% to 80% of SiO2, 12% to 25% of Al2O3, 0% to less than 1% of B2O3, 0% to 3% of Li2O+Na2O+K2O, 8% to 25% of MgO+CaO+SrO+BaO, 0.1% to 10% of P2O5, 0.1% to 20% of BaO, and 0.01% to 1% of SnO2, and having a strain point of more than 730° C., wherein the glass has a molar ratio (MgO+CaO+SrO+BaO)/Al2O3 of from 0.7 to 1.
US Pat. No. 10,655,000

HYDROGEL FORMING COMPOSITION AND HYDROGEL FORMED THEREOF

NISSAN CHEMICAL INDUSTRIE...

1. A hydrogel forming composition that is capable of forming a hydrogel having a self-supporting property, comprising:a water-soluble organic polymer having an organic acid structure, an organic acid salt structure, or an organic acid anion structure, and having a weight average molecular weight of 1,000,000 to 10,000,000;
a silicate salt, comprising water-swellable silicate salt particles selected from the group consisting of smectite and vermiculite;
a dispersant for the water-swellable silicate salt particles, comprising one or more selected from the group consisting of sodium polyacrylate having a weight average molecular weight of 1,000 to 20,000, ammonium poly(meth)acrylate, a sodium acrylate/sodium maleate copolymer, an ammonium acrylate/ammonium maleate copolymer, hydroxylamine, sodium carbonate, sodium silicate, polyethylene glycol, polypropylene glycol, sodium humate, and sodium ligninsulfonate; and
a compound having or generating divalent or higher valent positive charge, which is one or more selected from the group consisting of magnesium chloride, magnesium bromide, magnesium sulfate, magnesium nitrate, magnesium carbonate, magnesium acetate, a hydroxide of magnesium, an oxide of magnesium, a salt of calcium, a hydroxide of calcium, an oxide of calcium, a salt of aluminum, a hydroxide of aluminum, an oxide of aluminum, a diamine, and a salt of a diamine.
US Pat. No. 10,653,721

PEROXIDE FORMULATIONS AND METHODS AND APPLICATORS FOR USING THE SAME

ACLARIS THERAPEUTICS, INC...

1. A method of treating a wart in a human in need thereof comprising: topically administering to the wart of said human, a composition comprising about 45% w/w hydrogen peroxide and about 1% w/w to about 10% w/w 2-propanol.
US Pat. No. 10,655,001

HIGH DUCTILITY BLENDS OF PMMA AND POLYCARBONATE-SILOXANE COPOLYMER

SABIC Global Technologies...

1. A thermoplastic composition comprising:from about 5 wt % to about 70 wt % poly(methyl methacrylate) (PMMA);
from about 30 wt % to about 45 wt % of a first poly(carbonate-siloxane) copolymer having a siloxane content of from about 35 wt % to about 45 wt %; and
from about 25 wt % to about 40 wt % of a second poly(carbonate-siloxane) copolymer, wherein the second poly(carbonate-siloxane) copolymer has a siloxane content of from about 15 wt % to about 25 wt % or from about 4 wt % to about 8 wt %.
US Pat. No. 10,653,722

HUMAN CD8+ REGULATORY T CELLS INHIBIT GVHD AND PRESERVE GENERAL IMMUNITY

THE UNIVERSITY OF HONG KO...

1. A method for inhibiting a patient-recipient from rejecting a tissue graft or an organ transplant from a donor due to an allogeneic rejection, comprising:obtaining a sample of naïve CD8+CD25? T cells from the patient-recipient;
co-culturing activated B cells from the donor of the tissue graft or organ transplant with naïve CD8+CD25? T cells from the patient-recipient in a ratio of 1:2 to 1:25 for a period of time sufficient to generate alloantigen-specific human CD8hi regulatory T cells, wherein co-culturing is performed in the absence of exogenous cytokines; and
administering the alloantigen-specific human CD8hi regulatory T cells to the patient-recipient of the tissue graft or organ transplant.
US Pat. No. 10,653,723

PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF THE SAME IN IMMUNOTHERAPY

IOVANCE, BIOTHERAPEUTICS,...

1. A tumor infiltrating lymphocyte (TIL) pharmaceutical composition comprising:i) an expanded population of tumor infiltrating lymphocytes (TILs), and
ii) a pharmaceutically acceptable carrier;
wherein the expanded population of TILs is capable of exhibiting increased IFN-? secretion by at least one-fold in vitro as compared to a non-expanded population of TILs.
US Pat. No. 10,653,724

EXTRACELLULAR MATRIX FROM PLURIPOTENT CELLS

SanBio, Inc., Mountain V...

1. An isolated extracellular matrix (ECM) produced by a method comprising:(a) culturing cells on a culture surface for a predetermined period of time; and
(b) removing the cells from the culture surface;
wherein the cells are obtained by a method comprising:
(i) transfecting marrow adherent stromal cells with a nucleic acid comprising sequences encoding a Notch intracellular domain;
(ii) culturing the cells of step (i) in the presence of a selective agent, thereby selecting cells comprising the nucleic acid; and
(iii) further culturing the selected cells in the absence of the selective agent;
further wherein the isolated ECM supports growth of neurons to a greater extent than an ECM produced by a marrow adherent stromal cell.
US Pat. No. 10,653,725

METHODS FOR IMPROVING HEALTH OF FARMED FISH

Aker BioMarine Antarctic ...

1. A method of improving a parameter of heart health fish comprising:feeding fish a dietary ration comprising an amount of krill meal effective to improve one or more parameters of heart health in said fish, wherein the ration has a fatty acid content and from 2% to 10% of the fatty acids in the ration are eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) combined and the ratio of EPA to DHA is from 0.7 to 1.8.
US Pat. No. 10,653,726

COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING OXALATE-RELATED DISEASE

OXTHERA INTELLECTUAL PROP...

1. A method for reducing systemic circulating oxalate in a subject in need thereof, comprising orally administering a composition comprising oxalate decarboxylase in an amount effective to reduce the amount or concentration of oxalate in the gastrointestinal tract of said subject, wherein the administering of said composition is effected at least once per day for a period of months or years, wherein the method is effective to reduce systemic circulating oxalate in said subject.
US Pat. No. 10,654,750

CHEMICALLY TEMPERABLE GLASS SHEET

AGC GLASS EUROPE, Louvai...

1. A glass sheet having a boron-, strontium- and lithium-free glass composition, and comprising the following in weight percentage, expressed with respect to the total weight of glass:65?SiO2?78%;
5?Na2O?20%;
2?K2O<8%;
1?Al2O3<6%;
2?CaO<10%; and
0?MgO?8%;
as well as a total iron content, expressed in the form of Fe2O3, ranging from 0.027% to 0.06% by weight and a K2O/(K2O+Na2O) ratio which is from 0.2 to 0.62.
US Pat. No. 10,653,727

USE OF GRAM NEGATIVE SPECIES TO TREAT ATOPIC DERMATITIS

THE UNITED STATES OF AMER...

1. A pharmaceutical composition for treating atopic dermatitis comprising:at least one strain of Roseomonas mucosa, wherein the at least one strain of Roseomonas mucosa is viable, isolated, and present in an amount sufficient for treatment of atopic dermatitis in a subject in need thereof, wherein the at least one strain of Roseomonas mucosa comprises a nucleic acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, and SEQ ID NO: 3, and wherein the pharmaceutical composition is formulated for topical administration in a topical dosage form selected from the group consisting of a cream, gel, foam, ointment, and lotion.
US Pat. No. 10,653,728

PROBIOTIC COMPOSITIONS FOR IMPROVING METABOLISM AND IMMUNITY

NEW YORK UNIVERSITY, New...

1. A probiotic composition comprising (i) bacteria from one or more strains of the species Ileibacterium valens (I. valens) or a closely related operational taxonomic unit (OTU) which has at least 95% sequence identity to SEQ ID NO: 1 (NCBI GenBank Accession No. KU744404.1) over its entire length and (ii) a carrier and/or excipient and/or one or more prebiotic agents which stimulate growth and/or activity and/or preserve viability of one or more bacteria present in the composition.
US Pat. No. 10,656,544

ELECTROPHOTOGRAPH TONER

HEWLETT-PACKARD DEVELOPME...

1. A toner for electrophotography, the toner comprising:a toner particle including a binder resin, a colorant, and a releasing agent; and
an additive attached to an external surface of the toner particle, the additive comprising a quantum dot-inorganic particle composite including
inorganic particles attached to the external surface of the toner particle and
quantum dots attached to the inorganic particles, the quantum dots being more compatibly attachable to the inorganic particles than to the external surface of the toner particle.
US Pat. No. 10,653,729

DELIVERY SYSTEM AND PROBIOTIC COMPOSITION FOR ANIMALS AND PLANTS

NCH Corporation, Irving,...

1. An orally ingestible probiotic suspension composition for treating animals, the composition comprising:water;
one or more of Bacillus pumilus, Bacillus licheniformis, Bacillus amylophilus, Bacillus subtilis, Bacillus clausii, Bacillus firmus, Bacillus megaterium, Bacillus mesentericus, Bacillus subtilis var. natto, or Bacillus toyonensis in spore form;
one or more of citric, benzoic, sorbic, fumaric, or propionic acids or salts of these acids; and
a thickener;
wherein the composition comprises less than 1% total of the one or more acids or salts of acids by weight of the composition;
wherein the composition has a pH between 4.5 and 5.5; and
wherein all ingredients in the composition meet U.S. federal GRAS standards and the composition is storage stable with the bacteria remaining in spore form during storage for at least one month.
US Pat. No. 10,654,753

GYPSUM ADDITIVE TO CONTROL MERCURY

ECOLAB USA INC., St. Pau...

1. A method of treating synthetic gypsum, comprising:transporting the synthetic gypsum from a wet flue gas desulfurizer; and
contacting the synthetic gypsum with an additive, the additive comprising a sulfur-containing compound and water, wherein the sulfur-containing compound is a polymer comprising sulfur that is modified to contain at least one of a sulfide and a dithiocarbamate salt group.
US Pat. No. 10,656,545

TONER AND METHOD FOR PRODUCING TONER

CANON KABUSHIKI KAISHA, ...

1. A toner comprising a toner particle including a binder resin, whereinthe binder resin includes a polymer A,
the polymer A contains
a first monomer unit derived from a first polymerizable monomer, and
a second monomer unit derived from a second polymerizable monomer different from the first polymerizable monomer;
the first polymerizable monomer is at least one selected from the group consisting of (meth)acrylic acid esters having an alkyl group having 18 to 36 carbon atoms;
a content of the first monomer unit in the polymer A is 5.0 mol % to 60.0 mol %, based on the total number of moles of all the monomer units in the polymer A;
a content of the second monomer unit in the polymer A is 20.0 mol % to 95.0 mol %, based on the total number of moles of all the monomer units in the polymer A;
where an SP value of the first monomer unit is denoted by SP11 (J/cm3)0.5 and an SP value of the second monomer unit is denoted by SP21 (J/cm3)0.5, following formulas (1) and (2) are satisfied;
the polymer A includes a polyvalent metal;
the polyvalent metal is at least one selected from the group consisting of Mg, Ca, Al, and Zn; and
a content of the polyvalent metal in the toner particle is 25 ppm to 500 ppm on a mass basis,
3.00?(SP21?SP11)?25.00  (1), and
21.00?SP21  (2).
US Pat. No. 10,653,730

LACTIC ACID BACTERIUM, DRUG, FOOD OR DRINK, AND FEED WHICH CONTAIN THE LACTIC ACID BACTERIUM

MORINAGA MILK INDUSTRY CO...

1. A method for prophylaxis of a disease, comprising administering an agent that comprises cells of Lactobacillus paracasei MCC1849 (NITE BP-01633) to a subject in need thereof in an effective amount,wherein the disease is one or more selected from the group consisting of inflammatory, ulcer, food allergies, bronchial asthma, urticaria, pollinosis, anaphylactic shock and an opportunistic infection.
US Pat. No. 10,654,754

GYPSUM COMPOSITION FOR DRY-CURING COATING MATERIAL, GYPSUM-BASED COATING MATERIAL, AND CONSTRUCTION METHOD FOR GYPSUM-BASED COATING MATERIAL

YUSHINO GYPSUM CO., LTD.,...

1. A gypsum composition for a coating material for forming a coating film through drying the coating material, the gypsum composition comprising:hemihydrate gypsum having a mean particle diameter in a range of 50 ?m or less;
calcium carbonate having a mean particle diameter in a range of 50 ?m or less; and
a setting retarder,
wherein
the gypsum composition has a content of the calcium carbonate in a range from 10 to 400 parts by mass and a content of the setting retarder in a range of 0.1 parts by mass or more each relative to 100 parts by mass of the hemihydrate gypsum,
the hemihydrate gypsum comprises at least one material selected from the group consisting of ?-hemihydrate gypsum, ?-hemihydrate gypsum, and III-anhydrous gypsum, and
initial setting time of a hydration reaction that occurs when water is added to the gypsum composition so as to form a coating material is in a range of 24 hours or longer,
wherein the initial setting time of the hydration reaction is measured according to JIS A 6904, except that normal consistency in the JIS A 6904 is set at a penetration depth of 20±2 mm, and
the initial setting time of the hydration reaction corresponds to an initial setting in the JIS A 6904.
US Pat. No. 10,653,731

RECOMBINANTLY-MODIFIED ADENO-ASSOCIATED VIRUS (RAAV) HAVING IMPROVED PACKAGING EFFICIENCY

Vigene Biosciences Inc., ...

14. A method for increasing the production titer of recombinantly-modified adeno-associated virus (rAAV), wherein said method comprises:(A) employing, as said rAAV for producing said production titer, an rAAV that has been modified to comprise an added Cis-Element in one or more of its P1, P2, P3 or P4 Domains, wherein:
(1) said P1 Domain is 5? to a 5? ITR of said rAAV;
(2) said P2 Domain is 3? to said 5? ITR of said rAAV and 5? to a transgene cassette of said rAAV;
(3) said P3 Domain is 3? to said transgene cassette of said rAAV and 5? to a 3? ITR of said rAAV; and
(4) said P4 Domain is 3? to said 3? ITR of said rAAV;
wherein such added Cis-Element forms a G-Quadruplex Structure in said employed rAAV;
and
(B) culturing cells that have been transfected with said employed rAAV, wherein said cells additionally contain an AAV helper function-providing polynucleotide and a non-AAV helper function-providing polynucleotide, and wherein said culturing is conducted in a culture medium under conditions sufficient to permit the production of rAAV;
wherein the presence of such added Cis-Element in said employed rAAV causes said cells to produce said rAAV at an increased production titer relative to that which would be attained if said employed rAAV had lacked such added Cis-Element.
US Pat. No. 10,655,011

ANTISTATIC AND LIGHT-STABLE THERMOPLASTIC POLYCARBONATE MOULDING COMPOUNDS

Covestro Deutschland AG, ...

1. Compositions comprisingA) 50% to 90% by weight of at least one polymer selected from the group consisting of aromatic polycarbonate, aromatic polyestercarbonate and aromatic polyester,
B) 5% to 40% by weight of at least one polymer containing
B.1 at least one rubber-modified vinyl (co)polymer containing
B.1.1 80% to 95% by weight, based on the total weight of B.1, of at least one vinyl monomer and
B.1.2 5% to 20% by weight, based on the total weight of B.1, of one or more elastomeric polybutadiene-containing graft bases,
where B.1 contains
polybutadiene-containing rubber particles which have been grafted with the vinyl monomers B.1.1 and contain vinyl (co)polymer consisting of the vinyl monomers B.1.1 embedded within the rubber particles and cannot be leached out by means of standard solvents, and
a vinyl (co)polymer matrix consisting of the vinyl monomers B.1.1 which is not bound to these rubber particles and is not included in rubber particles,
and optionally B.2 further rubber particles grafted with vinyl monomers and composed of
B.2.1 5% to 75% by weight, based on the total weight of B.2, of at least one vinyl monomer and
B.2.2 25% to 95% by weight, based on the total weight of B.2, of one or more elastomeric graft bases,
C) 3% to 25% by weight of a mixture comprising a) at least one polyether-based polymer or copolymer selected from the group consisting of polyether block polymers and polyether-based polyurethanes and b) at least one boron-containing salt,
D) 0% to 2% by weight of at least one UV stabilizer selected from the group consisting of the substance classes of the benzotriazoles and triazines,
E) 0% to 20% by weight of one or more further additives,
wherein the compositions comprising components A) to E) have a polybutadiene content of 1% to 5% by weight.
US Pat. No. 10,653,733

NUTRITIONAL COMPOSITION

1. An orally administrable nutritional composition effective for both reducing cachectic symptoms and suppressing neoplastic growth in a cancer patient, comprising:5 ?g to 500 ?g selenium yeast;
0.5 mg to 1.5 g fish oil, the fish oil having a combined EPA/DHA content of between 10% to 90% and an EPA/DHA ratio of between 1:5 and 5:1;
500 iu to 10,000 iu beta carotene;
5 g to 13 g arginine;
10 g to 50 g glutamine;
6 g to 18 g lysine;
milk protein;
rice protein; and
inositol.
US Pat. No. 10,654,757

PROCESS FOR PREPARING A STORAGE-STABLE SILICONE RESIN

ELKEM SILICONES FRANCE SA...

1. A process for preparing a storage-stable mixture X comprising a silicone resin R, the process comprising the steps:a) preparing a mixture A from:
60 to 71% by weight of a chlorosilane of formula R1SiCl3,
15 to 25% by weight of a chlorosilane of formula (R2)2SiCl2,
7.5 to 20% by weight of a chlorosilane of formula (R3)3SiCl, and
optionally an aromatic hydrocarbon AH,
in which formulae the symbols R1, R2, and R3, which are identical or different, each represent:
a linear or branched alkyl radical containing from 1 to 8 carbon atoms,
a cycloalkyl radical containing from 5 to 8 ring carbon atoms, optionally substituted with at least one halogen,
an aryl radical containing from 6 to 12 carbon atoms which is optionally substituted with at least one halogen,
a radical with an alkyl part containing from 5 to 14 carbon atoms and an aryl part containing from 6 to 12 carbon atoms optionally substituted with at least one halogen, an alkyl containing from 1 to 6 carbon atoms and/or an alkoxyl containing from 1 to 3 carbon atoms,
a hydrogen atom, and
an alkenyl radical containing from 2 to 6 carbon atoms;
b) performing hydrolysis of the chlorosilanes of the mixture A to form the silicone resin R by adding the mixture A with stirring and while maintaining a temperature of between 5° C. and 60° C., to a two-phase mixture B comprised of an aqueous phase and a solvent phase, wherein the mixture B comprises water, an aromatic hydrocarbon AH and optionally an aqueous solution of hydrochloric acid CA;
c) optionally maintaining the stirring for at least 1 hour at a temperature of between 30° C. and 60° C. allowing a post-hydrolysis condensation reaction;
d) stopping the stirring to separate an aqueous phase and a solvent phase;
e) isolating and washing the solvent phase with water;
f) isolating the silicone resin R from the solvent phase; and
g) adding at least one organic compound O containing at least one epoxy group E which is an epoxidized fatty acid ester with stirring to the silicone resin R obtained in step f), and obtaining the mixture X;
wherein the resulting mixture X comprises:
i. the silicone resin R comprised of siloxyl units M, D and T with:
M being a siloxyl unit of formula: (Z1)3SiO1/2,
D being a siloxyl unit of formula: (Z2)2SiO2/2, and
T being a siloxyl unit of formula: Z3SiO3,
formulae in which the symbols Z1, Z2, and Z3, are identical or different, each represent:
a linear or branched alkyl radical containing from 1 to 8 carbon atoms,
a cycloalkyl radical containing from 5 to 8 carbon atoms, optionally substituted with at least one halogen,
an aryl radical containing from 6 to 12 carbon atoms, optionally substituted with at least one halogen,
a radical with an alkyl part containing from 5 to 14 carbon atoms and an aryl part containing from 6 to 12 carbon atoms optionally substituted with at least one halogen, an alkyl radical containing from 1 to 6 carbon atoms and/or an alkoxyl radical containing from 1 to 3 carbon atoms,
a hydroxyl radical,
a hydrogen atom, or
an alkenyl radical containing from 2 to 6 carbon atoms; and
with the condition that, for at least one unit D or T, at least one symbol Z2 or Z3 is a hydroxyl radical, and
ii. at least one organic compound O containing at least one epoxy group E.
US Pat. No. 10,653,734

DIETARY SUPPLEMENTS AND METHODS FOR TREATING PAIN AND INFLAMMATION

Melaleuca, Inc., Idaho F...

1. A dietary supplement for reducing pain, stiffness, or inflammation in a mammal, the dietary supplement comprising a mixture of:(a) about 37 mg to about 63 mg of Devil's Claw extract;
(b) about 16 mg to about 29 mg of Aronia extract;
(c) about 8 mg to about 16 mg of Angelica gigas extract and
(d) about 1 mg to about 50 mg of a turmeric extract.
US Pat. No. 10,655,014

SILOXANE RESIN COMPOSITIONS

WACKER CHEMIE AG, Munich...

1. A compositions comprising:(A) at least one organopolysiloxane comprising at least 3 units of the formula
R1aR2bR3cHd(RO)eSiO(4-a-b-c-d-e)/2  (I),whereR1 each independently are monovalent, SiC-bonded, optionally halogen- or cyano-substituted hydrocarbyl moieties with aliphatic carbon-carbon multiple bonding,
R2 each independently are monovalent, SiC-bonded, optionally halogen- or cyano-substituted, saturated hydrocarbyl moieties,
R3 each independently are monovalent SiC-bonded aromatic moieties,
R each independently are hydrogen or monovalent, optionally substituted hydrocarbyl moieties which are optionally interrupted by heteroatoms,
a is 0, 1, 2 or 3,
b is 0, 1, 2 or 3,
c is 0, 1, 2 or 3,
d is 0, 1 or 2, and
e is 0, 1 or 2,with the proviso that the a+b+c+d+e sum is not more than 3, the sum total of Si-bonded hydrogen atoms and R1 moieties per molecule is at least 3, the a+b+c+d sum is equal to 0 or 1 in at least 10 mol % of the units of formula (I), c is other than 0 in at least one unit, and the ratio of Si-bonded hydrogen atoms to Si-bonded R1 moieties in the siloxane (A) is from 0.1 to 9,optionally (B) organopolysiloxanes comprising units of the formulaR4fR5gR6h(R7O)tSiO(4-f-g-h-i)/2  (VI),whereR4 each independently are monovalent, SiC-bonded, optionally halogen- or cyano-substituted, hydrocarbyl moieties with aliphatic carbon-carbon multiple bonding,
R5 each independently are monovalent, SiC-bonded, optionally halogen- or cyano-substituted, saturated hydrocarbyl moieties,
R6 each independently are monovalent SiC-bonded aromatic moieties,
R7 each independently are hydrogen or monovalent, optionally substituted hydrocarbyl moieties, which are optionally interrupted by heteroatoms,
f is 0, 1, 2 or 3,
g is 0, 1, 2 or 3,
h is 0, 1 or 2,
i is 0 or 1,with the proviso that the f+g+h+i sum is not more than 3, siloxanes (B) have at least two R4 moieties per molecule, the f+g+h+i sum is equal to 0 or 1 in not more than 20 mol % of the units of formula (VI) and h is other than 0 in at least one unit of formula (VI),(C) at least one organopolysiloxane comprising units of the formula
R8kR9lR10m(R11O)nSiO(4-k-l-m-n)/2  (X),whereR8 each independently are monovalent, SiC-bonded, optionally halogen- or cyano-substituted, hydrocarbyl moieties with aliphatic carbon-carbon multiple bonding,
R9 each independently are monovalent, SiC-bonded, optionally halogen- or cyano-substituted, saturated hydrocarbyl moieties,
R10 each independently are monovalent SiC-bonded aromatic moieties,
R11 each independently are hydrogen or monovalent, optionally substituted hydrocarbyl moieties, which are optionally interrupted by heteroatoms,
k is 0, 1, 2 or 3,
l is 0, 1, 2 or 3,
m is 0, 1 or 2, and
n is 0 or 1,with the proviso that the k+l+m+n sum is not more than 3, siloxanes (C) have at least two R8 moieties per molecule, the k+l+m+n sum is equal to 0 or 1 in at least 10 mol % of the units of formula (X) and m is other than 0 in at least one unit of formula (X),and
optionally, (D) a catalyst which promotes the addition of Si-bonded hydrogen onto aliphatic carbon-carbon multiple bonds.
US Pat. No. 10,653,735

USES OF MESEMBRYANTHEMUM CRYSTALLINUM L. CALLUS EXTRACT IN DELAYING SKIN CELL AGING, NURSING SKIN, TREATING AND PREVENTING SKIN CANCER

TCI CO., LTD., Taipei (T...

1. A method for delaying skin aging, improving skin, and/or repairing skin in a subject in need thereof, comprising administering to said subject in need thereof an effective amount of a Mesembryanthemum crystallinum L. callus extract, wherein the extract is a polar solvent extract of Mesembryanthemum crystallinum L. callus.
US Pat. No. 10,655,015

TIRE CRUMB-BASED BITUMEN POLYMER FOR PRODUCING A LOWER VISCOSITY ASPHALT WITH IMPROVED TOLERANCE TO HIGH TEMPERATURES

Argopro Group LLC, New Y...

1. A bitumen additive for use in an asphalt, said bitumen additive comprising:about 70 to about 90 percent by weight of said entire bitumen additive of tire rubber crumbs sized about 14 mesh or smaller,
about 0.5 to about 5 percent by weight of said entire bitumen additive of a benzothiazole-based devulcanizing agent,
about 0.3 to about 3 percent by weight of said entire bitumen additive of a C14-C18 heavy metal soap,
about 0.1 to about 3 percent by weight of said entire bitumen additive of an antiozonant, and
about 0.1 to about 20 percent by weight of said entire bitumen additive of a plasticizer.
US Pat. No. 10,653,736

TOPICAL TREATMENTS INCORPORATING CANNABIS SP. DERIVED BOTANICAL DRUG PRODUCT

1. A topical formulation, consisting essentially of:an extract of Cannabis sativa or Cannabis indica;
at least one compound selected from the group consisting of menthol, resorcinol, and phenol, present in an amount of at least 0.1 wt % in the topical formulation,
wherein a concentration of at least one component selected from the group consisting of tetrahydrocannabinol and cannabidiol in the topical formulation is greater than 2 milligrams per kilogram, and
wherein the topical formulation is obtained by dispersing the extract of Cannabis sativa or Cannabis indica in a water-in-oil emulsion, an oil-in-water emulsion, a wax-in-oil base, or an oil-in-wax base.
US Pat. No. 10,655,272

COMPOSITION AND PROCESS FOR APPLYING HYDROPHOBIC COATING TO FIBROUS SUBSTRATES

Green Theme Technologies ...

1. A curable coating composition comprisinga) at least one free-radical-curable monomer having exactly one polymerizable group per molecule, the free-radical-curable monomer having at least one hydrocarbyl group that has at least eight carbon atoms bonded directly or indirectly to the polymerizable group, wherein the hydrocarbyl group may be nonfluorinated, partially fluorinated or perfluorinated, the free-radical-curable monomer having a boiling temperature equal to or greater than 100° C.,
b) at least one crosslinking monomer having at least two free-radical-curable polymerizable groups and a boiling temperature equal to or greater than 100° C.;
c) silicone oil; and
d) a heat-activatable free radical initiator,
wherein the coating composition is a liquid at 22° C. or a suspension of one or more solids in a liquid phase at 22° C., wherein the coating composition comprises, based on the total weight of the coating composition: 4 to 85 weight-% of component a), 2 to 25 weight-% of component b), 10 to 50 weight-% of the silicone oil, 1 to 10 weight percent of one or more the heat-activatable free-radical initiators and 0 to 35% of one or more functional attribute materials.
US Pat. No. 10,654,249

STYRENE COPOLYMER COMPOSITE FILM

INEOS STYROLUTION GROUP G...

1. A composite film having a thickness of not more than 1 mm comprising:(a) an acrylonitrile styrene acrylate (ASA) copolymer layer having a thickness of 50 to 500 ?m;
(b) a metal layer having a thickness of 0.1 to 50 ?m;
(c) optionally a coloured layer having a thickness of 0.1 to 50 ?m; and
(d) a transparent polymer layer that is a UV-protective, glossy, chemically inert or weatherproof layer and has a thickness of 0.5 to 50 ?m,
wherein said transparent polymer layer comprises one or more types of polystyrene, one or more types of styrene-acrylonitrile copolymer (SAN), one or more types of styrene-butadiene copolymer (SB), one or more types of acrylonitrile butadiene styrene copolymer (ABS), one or more types of polymethacrylate, one or more types of poly(methyl methacrylate), one or more types of (methyl)methacrylate-butadiene-styrene copolymer ((M)MBS), one or more types of acrylonitrile styrene acrylate (ASA), one or more types of styrene-maleic acid anhydride copolymer (SMA), one or more types of styrene-maleic acid anhydride-butadiene copolymer (SMAB), one or more types of styrene butadiene methylmethacrylate copolymer (SBMMA), one or more types of methyl methacrylate acrylonitrile butadiene copolymer, one or more types of polyethylene, one or more types of polypropylene, one or more types of polydimethylsiloxane (PDMS), one or more types of polylactone, one or more types of polyester, one or more types of poly(methyl methacrylate) (PMMA) or a blend of two or more thereof,
wherein layer (b) is located between layers (a) and (d) and optionally layer (c) is located between layers (b) and (d).
US Pat. No. 10,653,226

AEROSOL PRODUCT FOR FORMING WARMING CREAM COMPOSITION

TOYO AEROSOL INDUSTRY CO....

1. An aerosol product for forming a warming cream composition, comprising:a double structure container including a propellant filling space, two independent liquid concentrate filling spaces, and a discharging mechanism for simultaneously discharging contents filled in the two liquid concentrate filling spaces,
wherein
the propellant filling space in the double structure container is filled with a propellant composed of compressed gas;
a first liquid concentrate filling space in the double structure container is filled with a first liquid concentrate composition, and a second liquid concentrate filling space in the double structure container is filled with a second liquid concentrate composition;
the first liquid concentrate composition includes hydration exothermic substance powder dispersed in a liquid medium containing a polyhydric alcohol and a higher alcohol with 16 or more carbon atoms, wherein the liquid medium has a viscosity of 1000 to 10000 mPa·s at a temperature of 20° C., a content of the hydration exothermic substance powder is 10 to 40% by mass, a content of the higher alcohol is 0.05 to 20% by mass, the first liquid concentrate composition has a viscosity of 1000 to 125000 mPa·s at a temperature of 20° C., the hydration exothermic substance powder comprises at least one of zeolite, calcium chloride, magnesium chloride, magnesium sulfate, sodium carbonate, and silicic anhydride, the first liquid concentrate composition comprises substantially no water, and the first liquid concentrate composition comprises 0.05 to 0.87% by mass of a surfactant selected from the group consisting of an anionic surfactant, a nonionic surfactant having a HLB value of 6 to 13, and mixtures thereof;
the second liquid concentrate composition contains water and a viscosity modifier, wherein a content of the water is 90 to 99.9% by mass, a content of the viscosity modifier is 0.1 to 10% by mass; and
the first liquid concentrate composition discharged from the first liquid concentrate filling space and the second liquid concentrate composition discharged from the second liquid concentrate filling space are mixed with each other to form a warming cream composition.
US Pat. No. 10,653,738

TOPICAL MEDICATIONS FOR BRUISES AND BURNS

Meridian Research and Dev...

1. A topical skin healing medication comprising therapeutically effective amounts of silver sulfadiazine; diphenhydramine; lidocaine; and a petrolatum-based compounding agent.
US Pat. No. 10,655,018

SILICA SOL COMPOSITION HAVING EXCELLENT DISPERSIBILITY IN CYANATE-BASED RESIN AND METHOD FOR PREPARING SAME

LG CHEM, LTD., Seoul (KR...

1. A surface-modified silica sol composition comprising silica, an anionic dispersant, a cationic dispersant, an epoxy silane coupling agent, and an organic solvent,wherein the organic solvent is a mixed solvent of an aprotic polar organic solvent and a protic polar organic solvent, and the protic polar organic solvent is comprised in an amount of 0.001 to 10 wt % based on the total content of the mixed solvent,
the silica sol composition has a viscosity of 1 to 100 mPa*s,
the silica is comprised in an amount of 50 to 90 wt % based on the total content of the composition,
a surface of the silica is modified with the epoxy silane coupling agent, and
the epoxy silane coupling agent is included in an amount of 0.05 to 3 wt % based on the total content of the composition.
US Pat. No. 10,653,739

MEDICINAL AMBROSIA MARITIMA EXTRACTS

1. A method of treating bladder cancer or pancreatic cancer, comprising administering an effective amount of a composition comprising a clean organic extract of Ambrosia maritima together with a pharmaceutically acceptable carrier to a patient with bladder cancer or pancreatic cancer, whereby the clean organic extract of said Ambrosia maritima is prepared by treating a plant of Ambrosia maritima with a polar organic solvent, evaporating the polar organic solvent to produce a crude extract, subjecting the crude extract to chromatography using a second organic solvent to obtain said clean organic extract.
US Pat. No. 10,653,740

METHOD FOR TREATING FATTY LIVER

Amino Up Co., Ltd., Hokk...

1. A method of treating fatty liver comprising administering an effective amount of Cirsium brevicaule A. Gray, which is a plant belonging to a genus Cirsium, to a patient in need of the treatment.
US Pat. No. 10,658,094

NDFEB MAGNET CONTAINING CERIUM AND MANUFACTURING METHOD THEREOF

SHENYANG GENERAL MAGNETIC...

1. A method for manufacturing a NdFeB magnet containing cerium, comprising steps of:(a) sending a portion of raw materials, comprising pure iron, ferro-boron, and rare earth fluoride, into a crucible of a vacuum melting chamber under a vacuum condition, heating the portion of raw materials to a temperature of 1400-1500° C., and then refining the portion of raw materials;
(b) sending a rest of raw materials comprising the rare earth into the crucible of the vacuum melting chamber, injecting argon gas into the vacuum melting chamber, refining the raw materials in the crucible; casting a molten solution after refining to a surface of a water-cooled rotation roller through a tundish, and forming alloy flakes;
(c) sending at least two kinds of alloy flakes with different compositions into a hydrogen decrepitation furnace, and processing with a hydrogen decrepitation process; wherein: at least one kind of alloy flakes is prepared through the steps (a)-(b);
(d) sending the alloy flakes after the hydrogen decrepitation process into a nitrogen jet mill, and then milling the alloy flakes into powders by the nitrogen jet mill;
(e) under a protection of nitrogen, processing the powders with magnetic field pressing, and obtaining a pressed compact;
(f) under the protection of the nitrogen, sending the pressed compact into a vacuum sintering furnace, vacuum presintering the pressed compact, and obtaining a presintered block;
(g) machining the presintered block into a part; and
(h) processing the part with vacuum sintering and aging, and obtaining the NdFeB magnet containing cerium, wherein: a vacuum sintering temperature is controlled in a range of 960-1070° C., an aging temperature is controlled in a range of 460-640° C., a density of the NdFeB magnet containing cerium is 7.5-7.7 g/cm3, the average grain size is in the range of 3-7 ?m, the NdFeB magnet containing cerium comprises the main phase and the grain boundary phase distributed around the main phase, the main phase contains rare earth elements and contains at least La, Ce, Pr and Nd, the grain boundary phase contains Ce, N and F, the total weight percentage of La and Ce in the rare earth of the NdFeB magnet containing cerium is 1-69%, and the contents of N and F in the NdFeB magnet containing cerium are respectively 0.021 wt %?N?0.09 wt % and 0.004 wt %?F?0.5 wt %.
US Pat. No. 10,653,741

HERBO-MINERAL FORMULATION FOR THE TREATMENT OF CARDIO VASCULAR DISEASES AND METHOD OF PREPARATION THEREOF

Muniyal Ayurvedic Researc...

1. A formulation for treatment and management of Cardiovascular diseases, comprising:Terminalia arjuna, Sida rhombifolia, Withania somnifera, Tinospora cordifolia, Punica granatum, Emblica officinalis and Commiphora mukul, or extracts thereof, wherein Terminalia arjuna is present in an amount in the range of 8 to 12 wt %, Sida rhombifolia is present in an amount in the range of 2 to 6 wt %, Withania somnifera is present in an amount in the range of 2 to 6 wt %, Tinospora cordifolia is present in an amount in the range of 2 to 6 wt %, Punica granatum is present in an amount in the range of 2 to 6 wt %, Emblica officinalis is present in an amount in the range of 2 to 6 wt % and Commiphora mukul is present in an amount in the range of 2 to 6 wt %, of the total composition;
shilajit in an amount in the range of 1 to 3 wt % of the total composition; and
at least one bhasma selected from a group consisting of Muktasukti bhasma in an amount of ?2 wt %, Loha bhasma in an amount of ?2 wt %, Abhraka bhasma in an amount of ?3 wt %, Swarnamakshika bhasma in an amount of ?2 wt % and Pravala bhasma in an amount of ?2 wt %, of the total composition.
US Pat. No. 10,655,277

BIOPOLYMER COATING FOR COMPOSTABLE PAPERBOARD PACKAGING

WestRock MWV, LLC, Atlan...

1. A paperboard structure comprising:a paperboard substrate having a first surface and an opposed second surface; and
a heat sealable biopolymer coating applied by extrusion or co-extrusion to at least one of the first and second surfaces;
wherein the heat sealable biopolymer coating comprises an inorganic melt curtain stabilizer,
wherein the heat sealable biopolymer coating optionally further comprises an adhesion-promoting polymer, and
wherein the thickness of the heat sealable biopolymer coating is from 0.00025 to 0.005 inches.
US Pat. No. 10,653,742

ANTI-INFLAMMATORY USE OF LIQUID PHYTOCOMPLEXES FROM OLIVE

1. A method of using a composition comprising a concentrate of vegetation waters and/or olive pomace comprising 1-10 g/L of hydroxytyrosol and 0.5-8 g/L of 3,4-dihydroxyphenolethanol-elenolic acid di-aldehyde (3,4-DHPA-EDA) to treat and/or prevent inflammation, comprising the step of administering the composition to a patient in need thereof, wherein the composition treats and/or prevents inflammation, wherein the inflammation is a non- tumor inflammation selected from the group consisting of inflammatory diseases of the colon-rectum, bronchial pathologies, liver diseases, diseases of the prostate, mucositis, and pre-neoplastic lesions.
US Pat. No. 10,654,766

PROCESS FOR MAKING VINYLIDENE OLEFIN

ExxonMobil Chemical Paten...

1. A continuous process for making a vinylidene olefin dimer from a terminal olefin comprising at least eight (8) carbon atoms per molecule, comprising:feeding a monomer stream comprising the terminal olefin into a reactor at a first feeding rate of R(to) moles of the terminal olefin per hour;
feeding a metallocene compound having a formula Cp(Bg)nMX2Cp? into the reactor at a second feeding rate of R(mc) moles of the metallocene compound per hour, wherein M is selected from Hf and Zr; each X is independently a halogen or a hydrocarbyl group; Cp and Cp?, the same or different, independently represents a cyclopentadienyl, alkyl-substituted cyclopentadienyl, indenyl, alkyl-substituted indenyl, 4,5,6,7-tetrahydro-2H-indenyl, alkyl-substituted 4,5,6,7-tetrahydro-2H-indenyl, 9H-fluorenyl, and alkyl-substituted 9H-fluorenyl; each Bg is a bridging group covalently linking Cp and Cp?; and n is 0, 1, or 2;
feeding an alumoxane feed into the reactor at a third feeding rate corresponding to R(Al) moles of aluminum atoms per hour, wherein the alumoxane feed comprises metal elements other than aluminum, alkali metals, alkaline earth metals, and the metal contained in the metallocene compound at a total concentration no greater than 50,000 ppm by mole, based on the total moles of all metal atoms present in the alumoxane feed;
conducting oligomerization reaction in the reactor at a temperature in the range from 50 to 90° C., wherein the oligomerization reaction has a conversion of the terminal olefin of no less than 70%;
drawing a stream of oligomerization reaction mixture from the reactor comprising unreacted terminal olefin, a dimer of the terminal olefin, and a trimer of the terminal olefin, wherein:
the first feeding rate, the second feeding rate, and the third feeding rate are chosen such that:
350 2?R(Al)/R(mc)?10,
the oligomerization reaction has a selectivity of the terminal olefin toward trimer no greater than 5% and
the oligomerization reaction has a selectivity of the terminal olefin toward dimers of at least 95%; wherein the dimers comprise the vinylidene olefin dimer.
US Pat. No. 10,655,022

POWDER COATING MATERIAL, METHOD FOR PRODUCING POWDER COATING MATERIAL, AND COATED ARTICLE

AGC Inc., Chiyoda-ku (JP...

1. A powder coating material comprising a resin powder component containing a fluorinated copolymer which has repeating units based on a fluoroolefin and repeating units based on a monomer having no fluorine atom, and which has a fluorine content of at least 10 mass %, and a plasticizer-covered luster pigment composed of luster pigment particles with their surface covered by a plasticizer, whereinthe plasticizer is a plasticizer which has a melting point of from 30 to 200° C. and a molecular weight of from 200 to 1,000, and which has from 1 to 4 ester groups in one molecule.
US Pat. No. 10,654,767

PROCESS FOR PRODUCING ALKYLATED AROMATIC HYDROCARBONS FROM A MIXED HYDROCARBON FEEDSTREAM

SABIC Global Technologies...

1. A process for producing alkylated aromatic hydrocarbons comprising:(a) subjecting a mixed hydrocarbon feedstream to a separation to provide a C6 cut;
(b) subjecting the C6 cut to hydrocracking, wherein the hydrocracking comprises contacting the C6 cut with a hydrocracking catalyst comprising a hydrogenation metal and a zeolite under hydrocracking conditions comprising a temperature of 450-580° C., a pressure of 300-5000 kPa gauge, and a Weight Hourly Space Velocity of 0.1-20 h1 to provide a benzene stream, wherein the benzene stream has a benzene purity of at least 98 wt %; and
(c) subjecting the benzene stream to alkylation to provide a product stream rich in alkylated aromatic hydrocarbons.
US Pat. No. 10,655,023

ELECTRODEPOSITION SYSTEM

The Sherwin Williams Comp...

12. A method for electrodeposition, comprising:providing an emulsion including a cationizable electrodeposition resin component and a blocked polyisocyanate crosslinker component; providing a pigment paste including a dispersion resin, pigment, and an inorganic bismuth salt of a metal oxyanion bismuth-containing compound comprising bismuth aluminate.
US Pat. No. 10,653,744

FORMULATIONS AND METHODS FOR TREATING ULCERATIVE COLITIS

Bausch Health Ireland Lim...

1. A method for preventing, treating, or alleviating a symptom of ulcerative colitis, the method comprising rectally administering once daily for at least 28 days to a subject in need thereof a therapeutically effective amount of a composition comprising 6 mg of dolcanatide (SEQ ID NO: 9), and inducing remission of the symptoms of ulcerative colitis in the subject.
US Pat. No. 10,653,745

TREATMENT OF RHINOSINUSITIS WITH P-GLYCOPROTEIN INHIBITORS

Massachusetts Eye and Ear...

1. A method of treating chronic rhinosinusitis in a subject, the method comprising:identifying a subject having chronic rhinosinusitis;
administering to the subject an effective amount of a P-glycoprotein inhibitor,
wherein the P-glycoprotein inhibitor is not an antibiotic agent, an antifungal agent, a corticosteroid, or a first generation P-glycoprotein inhibitor compound.
US Pat. No. 10,653,746

MEDICAMENT FOR USE IN TREATING GOUT

Baozhen Xu, Shandong (CN...

1. A medicament for use in treating gout comprising:78 parts by weight of a glycoprotein extracted from marine blue-green algae,
10 parts by weight of ligusticum wallichii,
8 parts by weight of alismatis rhizoma,
6 parts by weight of cimicifuga foetida,
7 parts by weight of glabrousleaf pittosporum leaf,
7 parts by weight of notoperygium root, and
5 parts by weight of Chinese clematis root.
US Pat. No. 10,655,026

WATER-BASED COATINGS

Sun Chemical Corporation,...

1. A water-based printing ink or coating composition comprising an acrylic resin emulsion and an epoxy ester resin dispersion wherein the acrylic resin in the acrylic resin emulsion consists of an acrylic resin that has the general formula I:[—CH2—CH(CO2C4H9)—]V[—CH2—C(CH3)(CO2(CH3)—]W[—CH2—CH(C6H5)—]X
[—CH2—CH(CONHC(CH3)2(CH2COCH3)—]Y[—CH2—C(CH3)(CO2H)—]Z   Formula I
and wherein the monomer units v, w, x, y and z are present in the copolymer in the amounts of v between 10-50 wt %, w between 10-50 wt %, x between 10-30 wt %, y between 1-10 wt % and z between 0.1-5 wt %; and
wherein the ink or coating composition comprises between 10-30 wt % of acrylic resin emulsion, and between 5-75 wt % of epoxy ester resin dispersion.
US Pat. No. 10,653,747

APOE MIMETIC PEPTIDES AND HIGHER POTENCY TO CLEAR PLASMA CHOLESTEROL

UAB RESEARCH FOUNDATION, ...

1. A synthetic apolipoprotein E(ApoE)-mimicking peptide comprising a receptor binding domain of ApoE and a lipid-associating peptide, wherein the synthetic ApoE-mimicking peptide comprises a fatty acid moiety, a ?-amino fatty acid moiety, or an acetylated ?-amino fatty acid moiety, wherein the lipid-associating peptide comprises a class A amphipathic helical domain, wherein the fatty acid moiety is a saturated fatty acid moiety, wherein the receptor binding domain of ApoE is on the N-terminus of the synthetic ApoE-mimicking peptide, and wherein the saturated fatty acid moiety is at the N-terminus of the receptor binding domain of ApoE.
US Pat. No. 10,655,027

FREE RADICAL RADIATION CURABLE LIQUIDS FOR DE-INKING SUBSTRATES

AGFA GEVAERT NV, Mortsel...

1. A method of inkjet printing a packaging material with an inkjet ink set including a free radical radiation curable liquid and at least a cyan inkjet ink, a magenta inkjet ink, a yellow inkjet ink, and a black inkjet ink, the method comprising the steps of:jetting on a substrate the free radical radiation curable liquid including a photoinitiator and a monomer including an alkali hydrolyzable group or an oligomer including an alkali hydrolyzable group; and
at least partially curing the free radical radiation curable liquid; wherein
the alkali hydrolyzable group is located in an atomic chain between two free radical polymerizable groups of the monomer or the oligomer;
the alkali hydrolyzable group is an oxalate group; and
the substrate is the packaging material.
US Pat. No. 10,653,748

COMPOSITIONS AND METHODS FOR ADJOINING TYPE I AND TYPE II EXTRACELLULAR DOMAINS AS HETEROLOGOUS CHIMERIC PROTEINS

Heat Biologics, Inc., Du...

1. A method for treating cancer comprising administering an effective amount of a pharmaceutical composition to a subject in need thereof, the pharmaceutical composition comprising a heterologous chimeric protein comprising:(a) a first domain comprising a portion of programmed cell death protein 1 (PD-1) that is capable of binding a PD-1 ligand,
(b) a second domain comprising a portion of 4-1BB ligand (4-1BBL) that is capable of binding a 4-1BBL receptor, and
(c) a linker linking the first domain and the second domain and comprising a hinge-CH2-CH3 Fc domain.
US Pat. No. 10,654,004

HIGH FLUX REVERSE OSMOSIS MEMBRANE COMPRISING POLYETHERSULFONE/POLYETHYLENE OXIDE-POLYSILSESQUIOXANE BLEND MEMBRANE FOR WATER PURIFICATION

1. A membrane comprising a nanoporous polyethersulfone/polyethylene oxide-polysilsesquioxane blend support membrane comprising a polyethylene oxide-polysilsesquioxane polymer and a polyethersulfone polymer, a hydrophilic polymer inside the pores on the skin layer surface of said nanoporous polyethersulfone/polyethylene oxide-polysilsesquioxane blend support membrane; and a layer of cross-linked polyamide on the skin layer surface of said nanoporous polyethersulfone/polyethylene oxide-polysilsesquioxane blend support membrane.
US Pat. No. 10,653,749

TARGETING GIV-GEF-GI SIGNALING FOR TREATING DIVERSE DISEASES

The Regents of the Univer...

1. A cell-permeable peptide PTD-GIV-CT comprising (i) a peptide transduction domain (PTD) and (ii) a C-terminus of G?-Interacting Vesicle associated protein (GIV-CT) or a mutant thereof, wherein said peptide is capable of activating Gi downstream of receptor tyrosine kinases (RTKs), wherein the PTD is connected to the GIV-CT via a linker sequence, and wherein the linker sequence comprises the sequence GGSGHSG (SEQ ID NO: 11).
US Pat. No. 10,653,750

USE OF CCL2 TO INHIBIT ABNORMAL UTERINE BLEEDING

UNIVERSITY OF SOUTH FLORI...

1. A method for reversing long acting progestin-only contraceptive (LAPC)-induced inhibition of vascular smooth muscle cell (VSMC) proliferation in a subject, comprising administering an effective amount of chemokine (C-C motif) ligand 2 (CCL2) and the LAPC to the subject, wherein the CCL2 comprises a CCL2 polypeptide comprising amino acids 24-99 of SEQ ID NO: 1.
US Pat. No. 10,653,751

METHODS OF TREATING CANCER METASTASIS BY USING INTERLEUKIN-10

Armo Biosciences Inc., R...

1. A method of treating metastasis or inhibiting metastasis of a primary tumor in a human subject, the method comprising administering to the subject a therapeutically effective amount of an IL-10 agent, wherein the amount of IL-10 agent administered daily is in a range of about 20 ?g/kg to about 40 ?g/kg wherein the administering is effective to treat metastasis or inhibit metastasis of the primary tumor in the subject, and wherein the primary tumor is a cancer selected from the group consisting of pancreatic cancer, colon cancer, kidney cancer, breast cancer, lung cancer, prostate cancer and melanoma.
US Pat. No. 10,654,775

SEPARATION METHOD FOR HALOGENATED UNSATURATED CARBON COMPOUND

DAIKIN INDUSTRIES, LTD., ...

1. A method for separating an unsaturated hydrocarbon having 2 or 3 carbon atoms and a halogenated unsaturated carbon compound having 2 or 3 carbon atoms from each other, the method comprising:contacting a porous coordination polymer with a mixture including both the unsaturated hydrocarbon having 2 or 3 carbon atoms and the halogenated unsaturated carbon compound having 2 or 3 carbon atoms, wherein
either the unsaturated hydrocarbon or the halogenated unsaturated carbon compound is selectively adsorbed to the porous coordination polymer, and
the porous coordination polymer is represented by a composition formula [Cr3O(OH)(bdc)3] where bdc is 1,4-benzenedicarboxylate, [Zr6O4(OH)4(bpdc)6] where bpdc is 4,4?-biphenyldicarboxylate, or [Ni2(dhtp)] where dhtp is 2,5-dihydroxyterephthalate.
US Pat. No. 10,653,752

METHODS AND USE OF GROWTH HORMONE SUPERGENE FAMILY PROTEIN ANALOGS FOR TREATMENT OF RADIATION EXPOSURE

Bolder Bio Technology, In...

1. A method for improving survival from radiation exposure in a subject who has been exposed to radiation and has been diagnosed as having Acute Radiation Syndrome (ARS) by administering to the subject an effective dose of a long-acting human granulocyte-macrophage colony-stimulating factor (GM-CSF) protein analog comprising a cysteine residue substituted for alanine-3 of SEQ ID NO: 2, and wherein the long-acting human GM-CSF protein analog is modified with a single polyethylene glycol (PEG).
US Pat. No. 10,653,753

TREATMENT OF HYPERINSULINEMIC HYPOGLYCEMIA WITH EXENDIN-4 DERIVATIVES

Eiger Biopharmaceuticals,...

1. A method of treating hyperinsulinemic hypoglycemia, the method comprising administering an exendin-4 derivative to a patient in need thereof, wherein the exendin-4 derivative is selected from the group consisting of exendin(3-39), exendin(4-39), exendin(5-39), exendin(6-39), exendin(7-39), and exendin(8-39), and wherein the exendin-4 derivative is administered at a dose of 0.01 mg to 50 mg.
US Pat. No. 10,654,777

INTEGRATED PROCESS FOR THE PRODUCTION OF Z-1,1,1,4,4,4-HEXAFLUORO-2-BUTENE

THE CHEMOURS COMPANY FC, ...

1. A process for the preparation of fluorine-containing olefins comprising contacting a chlorofluoroalkene having the formula E- and Z—CF3CCl=CClCF3 with hydrogen in the presence of a catalyst comprising copper and palladium on a support, wherein the catalyst comprises 0.1 to 1.0 weight percent palladium and 0.1 to 20 weight percent copper, at a temperature of from about 150° C. to 250° C., to produce a product mixture comprising a fluorine-containing olefin having the formula E- or Z—CF3CH?CClCF3, or a mixture thereof.
US Pat. No. 10,655,033

FLOOR COATING COMPOSITION

Dow Global Technologies L...

1. A floor coating composition, comprising:(a) an aqueous dispersion of thermoplastic polymer particles imbibed with a thermosettable compound having at least two oxirane groups, which polymer particles are characterized by having a sufficient concentration of anti-agglomerating functional groups to stabilize the dispersion against agglomeration, wherein the concentration of the anti-agglomerating functional groups is from 0.5% to 10% by weight, based on the weight of the polymer particles;
(b) a waterborne amine hardener, wherein the waterborne amine hardener comprises a polyamine adduct comprising at least one ethylene oxide segment and the waterborne amine hardener, when diluted with deionized water at 25° C. to form a diluted hardener having a calculated amine hydrogen equivalent weight of 126,250 g/eq, has a zeta potential of from ?50 mV to 22 mV; and
(c) a first filler present in an amount of from 60% to 90% by weight, based on the total solids weight of the floor coating composition, wherein the first filler has a sieve particle size of from 75 ?m to 270 ?m.
US Pat. No. 10,653,754

HIGHLY PURE NEUROTOXIC COMPONENT OF A BOTULINUM TOXIN AND USES THEREOF

Merz Pharmaceuticals GmbH...

1. A highly pure neurotoxic component of a Clostridium botulinum toxin having a single-chain content of less than 1.70 wt. %, and a total purity of at least 99.90 wt. %.
US Pat. No. 10,654,778

METHOD FOR PRODUCING 1-CHLORO-2,3,3-TRIFLUOROPROPENE

AGC Inc., Chiyoda-ku (JP...

1. A method for producing 1-chloro-2,3,3-trifluoropropene, comprising:contacting a composition comprising 1-chloro-2,3,3-trifluoropropene and at least one member selected from the group consisting of 1-chloro-3,3-difluoro-1-propyne and an oxide, with a basic aqueous solution at a temperature of from 20° C. to 40° C., thereby removing the at least one member from the composition,
wherein a content of the 1-chloro-2,3,3-trifluoropropene in the composition is at least 80 mass %.
US Pat. No. 10,655,034

UV-CURABLE SILSESQUIOXANE-CONTAINING WRITE-THROUGH OPTICAL FIBER COATINGS FOR FABRICATION OF OPTICAL FIBER BRAGG GRATINGS, AND FIBERS MADE THEREFROM

OFS FITEL, LLC, Norcross...

1. A coated article comprising:the reaction product of a coating composition comprising a polyhedral cage silsesquioxane component having one or more reactive functional groups that render it curable using ultraviolet radiation; where the one or more reactive functional groups are acrylates; and
optionally, a co-reactive non-silsesquioxane monomer and/or an oligomer having one or more reactive functional groups that are curable using ultraviolet radiation and are free radically curable acrylate; where the coating composition is disposed and cured on an optical article to form the coating; where the optical article is at least one of an optical fiber or an optical planar waveguide; and where the average functionality of the coating composition is greater than one.
US Pat. No. 10,656,314

MOLDED ARTICLE, THERMOPLASTIC RESIN COMPOSITION, AND DISPLAY DEVICE

Mitsubishi Chemical Corpo...

1. A shaped article in which an L* value of reflected light is 35 or less, wherein:the shaped article is obtained by molding a thermoplastic resin composition comprising:
a thermoplastic resin; and
two or more kinds of light absorbing agents each of which has a maximum absorbance wavelength different from each other, provided that the maximum absorbance wavelength is a wavelength at which the maximum value of light absorbance is exhibited in a wavelength range of 380 nm or more to 880 nm or less,
wherein the thermoplastic resin is an acrylic resin,
at least one of the light absorbing agents comprises a light absorbing agent (B) which has the maximum absorbance wavelength in a wavelength range of 450 nm or more and less than 700 nm, and a total content of the light absorbing agent (B) is 0.1 part by mass or more and 0.5 part by mass or less relative to 100 parts by mass of the thermoplastic resin,
a total light transmittance of the shaped article is 1% or less, and
in a wavelength range of 380 nm or more to 780 nm or less, the wavelength at which the maximum value of light transmittance is exhibited for the shaped article is in a range of 380 nm or more to less than 680 nm, and Formulae (1) and (2) are satisfied
Formula (1):
T??0.1%  (1)
Formula (2):
0%?T??T?/2  (2)
wherein in the formulae, T? is the maximum value of light transmittance in a wavelength range of 380 nm or more to less than 680 nm, and T? is the maximum value of light transmittance in a wavelength range of 680 nm or more to 780 nm or less.
US Pat. No. 10,653,755

COMPOSITIONS AND METHODS FOR TREATMENT OF HOMOCYSTINURIA

THE REGENTS OF THE UNIVER...

1. A method of treating homocystinuria in a subject, said method comprising administering to a subject a composition comprising an isolated human C-terminal truncated cystathionine beta synthase (htCBS) mutant polypeptide having a C15S mutation, wherein the isolated htCBS mutant polypeptide has been PEGylated, and wherein the isolated htCBS mutant polypeptide is administered in a dose between about 0.01 and about 10 mg/kg.
US Pat. No. 10,653,756

IDENTIFICATION OF CD8+ T CELLS THAT ARE CD161HI AND/OR IL18R(?)HI AND HAVE RAPID DRUG EFFLUX CAPACITY

Fred Hutchinson Cancer Re...

1. A composition comprising an isolated population of long-lived human memory CD8+ CD161hi IL-18R?hi T cells, wherein:the long-lived memory CD8+ CD161hi IL-18R?hi T cells make up at least 30% of the total CD8+ T cells in the composition; and
the long-lived memory CD8+ CD161hi IL-18R?hi T cells comprise CD95hi memory cells, wherein the CD95hi memory cells are capable of proliferating in response to IL-7 or IL-15 and comprise a population of cells comprising an engineered immunoreceptor.
US Pat. No. 10,653,757

METHODS AND COMPOSITIONS FOR VACCINATING AGAINST STAPHYLOCOCCUS AUREUS

NovaDigm Therapeutics, In...

1. A method of treating a skin abscess caused by Staphylococcus aureus in a human in need thereof comprisingadministering to said human an effective amount of an immunogenic composition comprising 30 to 300 micrograms of an isolated polypeptide consisting of the N-terminal domain of Candida albicans agglutinin-like sequence 3 protein (Als3p), wherein the N-terminal domain extends from the end of the signal peptide to the beginning of the tandem repeats of the Candida albicans Als3p, in a pharmaceutically acceptable medium, wherein the composition elicits an immune response in said human against the S. aureus that decreases the area and severity of the skin abscess.
US Pat. No. 10,654,781

METHOD OF CATALYTIC CONVERSION OF CARBOHYDRATES TO LOW-CARBON DIOLS BY USING ALLOY CATALYSTS

DALIAN INSTITUTE OF CHEMI...

1. A method for catalytic conversion of carbohydrates to low-carbon diols, comprising: subjecting a carbohydrate feedstock to catalytic hydrogenation at an elevated pressure in water in the presence of an alloy catalyst,wherein the alloy catalyst consists of tin and one or more transition metals selected from the group consisting of nickel, iron, cobalt, rhodium, ruthenium, palladium, iridium, copper, and a mixture thereof,wherein a weight ratio between tin and the one or more transition metals is in a range of 0.01-100,wherein the catalytic hydrogenation reaction is conducted in a reactor filled with hydrogen at a temperature higher than 120° C. for a reaction time no less than 5 minutes or at a liquid hourly space velocity of not more than 20 h?1,wherein a weight concentration of the alloy catalyst in the reaction system is between 0.1 wt % and 50 wt %, andwherein the low-carbon diol comprises ethylene glycol and 1,2-propylene glycol, wherein a yield of ethylene glycol is higher than a yield of 1,2-propylene glycol, and wherein tin in the alloy is metallic.
US Pat. No. 10,655,037

ADHESIVE COMPOSITION FOR POLARIZING PLATE, ADHESIVE FILM FOR POLARIZING PLATE COMPRISING THE SAME, POLARIZING PLATE COMPRISING THE SAME AND DISPLAY DEVICE COMPRISING THE SAME

SAMSUNG SDI CO., LTD., Y...

1. An adhesive composition for a polarizing plate, comprising:(A) a polymerizable functional group-containing monomer capable of providing an anchor effect comprising (A1) a polymerizable functional group-containing macromonomer;
(B) an epoxy group-containing compound comprising a (meth)acrylate having one epoxy group;
(C) optionally, a (meth)acrylic-based monomer;
(D) a photoacid generator; and
(E) at least one chosen from a photopolymerization initiator and a photosensitizer,
wherein the adhesive composition comprises (A1) the polymerizable functional group-containing macromonomer in an amount of about 0.5 parts by weight to about 30 parts by weight, with respect to 100 parts by weight of (A)+(B)+(C), and (B) the epoxy group-containing compound in an amount of about 40 parts by weight to about 99.5 parts by weight with respect to 100 parts by weight of (A)+(B)+(C).
US Pat. No. 10,653,758

DISEASE THERAPY USING A TOLEROGENIC PHARMACEUTICAL PREPARATION

INSTITUT NATIONAL DE LA S...

1. A method comprising administering a therapeutically effective amount of a supernatant to an individual in need of therapy for a pathological immune response, wherein:the supernatant is from a co-culture of viable phagocytes with apoptotic cells, wherein the apoptotic cells are apoptotic thymocytes;
the phagocytes comprise monocyte-derived macrophages;
the phagocytes are from a phagocyte cell preparation in which phagocytes represent 20% to 100% of the cells of the phagocyte cell preparation;
the pathological immune response is an auto-immune disease, a transplantation-related disease, or an inflammation-associated disease; and
the supernatant is obtained by a method that comprises:
co-culturing the phagocytes with the apoptotic cells in a physiological solution until anti-inflammatory compounds are present, where the phagocytes and apoptotic cells in the co-culture are present in a ratio of 1:4, 1:5, or 1:6.
US Pat. No. 10,654,782

METHOD FOR THE PRODUCTION OF GLYCOLS FROM A CARBOHYDRATE FEED

Shell Oil Company, Houst...

1. A method for producing ethylene glycol from a carbohydrate feed comprising:a) contacting, in a first reactor under hydrogenation conditions, the carbohydrate feed with a bi-functional catalyst system comprising:
1) a heterogeneous hydrogenation catalyst, and
2) a soluble retro-Aldol catalyst;
and, wherein the carbohydrate feed comprises a concentration of carbohydrate, in the total solution entering the first reactor, of 5-40 wt % in a solvent;
b) running the reaction under pH controlled conditions for at least 24 hours and wherein the pH of the reaction is in the range of from 2-7, wherein the pH is controlled using at least one pH controlling agent selected from the group consisting of: alkali- and alkaline-earth metal salts of carbonic acid or carboxylic acids or combinations thereof, alkali- and alkaline-earth metal salts of phosphoric acid, zinc carbonate, and zinc salts of carboxylic acids;
c) obtaining an intermediate product stream, from the first reactor, comprising ethylene glycol; and wherein the hydrogenation conditions comprise a temperature in the range of from 180-250° C.
US Pat. No. 10,653,759

METHODS, ANTIBODIES, AND VACCINES UTILIZING EPITOPES OF ALPHA SYNUCLEIN FOR TREATMENT OF PARKINSON'S DISEASE

UNIVERSITY OF SOUTH FLORI...

1. A composition for inhibiting Parkinson's disease induced neurodegeneration, the composition comprising an isolated human dendritic cell, wherein the human dendritic cell is sensitized to a peptide fragment consisting of SEQ ID NO:3, andat least one antibody generated by a method comprising:
providing a non-human host organism;
immunizing said host organism with a peptide comprising an amino acid sequence of SEQ ID NO:1, SEQ ID NO:2, or a combination thereof; and
isolating from said host organism at least one antibody to SEQ ID NO:1 and/or SEQ ID NO:2.
US Pat. No. 10,654,783

CRYSTALLINE POLYMORPHS OF 1,6-DIBROMO-1,6-DIDEOXY-DULCITOL

Targent, LLC, Princeton,...

1. A crystalline polymorph of 1,6-dibromo-1,6-dideoxy-dulcitol (DBD), wherein the crystalline polymorph exhibits an X-Ray Powder Diffraction Pattern substantially the same as the X-Ray Powder Diffraction Pattern shown in FIG. 1 and/or FIG. 2.
US Pat. No. 10,653,760

COMPOSITIONS AND METHODS FOR REDUCING ORGAN REJECTION BY REDUCING HEPARAN SULFATE IN DONOR TRANSPLANTS

University of Florida Res...

1. A method of treating or reducing rejection of a transplant, the method comprising contacting an organ with a therapeutically effective amount of a polypeptide comprising the sequence set forth in SEQ ID NO: 2 or 3.
US Pat. No. 10,654,784

PROCESS FOR HYDROFORMYLATING SHORT-CHAIN OLEFINS IN THE GAS PHASE

Evonik Operations GmbH, ...

1. A process for hydroformylating C2 to C8 olefins in a reaction zone using a heterogenized catalyst system, wherein the process isa gaseous feed mixture containing the C2 to C8 olefins is passed together with synthesis gas over a support composed of a porous ceramic material on which the catalyst system comprising a metal from group 8 or 9 of the Periodic Table of the Elements, at least one organic phosphorus-containing ligand, a stabilizer and optionally an ionic liquid is in heterogenized form; and
the support is a block of a ceramic material, to which a washcoat composed of the same or a different ceramic material with respect to the ceramic material of the support is applied.
US Pat. No. 10,653,761

PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST CLL AND OTHER CANCERS

IMMATICS BIOTECHNOLOGIES ...

1. A method of eliciting an immune response in a patient who has cancer, comprising administering to the patient a composition comprising a population of activated T cells that kill the cancer cells that present a peptide consisting of the amino acid sequence of SEQ ID NO: 86,wherein said cancer is selected from the group consisting of glioblastoma, breast cancer, colorectal cancer, renal cell carcinoma, chronic lymphocytic leukemia, hepatocellular carcinoma, non-small cell and small cell lung cancer, non-Hodgkin lymphoma, acute myeloid leukemia, ovarian cancer, pancreatic cancer, prostate cancer, esophageal cancer, gallbladder cancer and cholangiocarcinoma, melanoma, gastric cancer, testis cancer, urinary bladder cancer, head and neck squamous cell carcinoma, and uterine cancer.
US Pat. No. 10,653,762

PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST CLL AND OTHER CANCERS

IMMATICS BIOTECHNOLOGIES ...

1. A method of eliciting an immune response in a patient who has cancer, comprising administering to the patient a composition comprising a population of activated T cells that kill the cancer cells that present a peptide consisting of the amino acid sequence of SEQ ID NO: 66,wherein said cancer is selected from the group consisting of glioblastoma, breast cancer, colorectal cancer, renal cell carcinoma, chronic lymphocytic leukemia, hepatocellular carcinoma, non-small cell and small cell lung cancer, non-Hodgkin lymphoma, acute myeloid leukemia, ovarian cancer, pancreatic cancer, prostate cancer, esophageal cancer, gallbladder cancer and cholangiocarcinoma, melanoma, gastric cancer, testis cancer, urinary bladder cancer, head and neck squamous cell carcinoma, and uterine cancer.
US Pat. No. 10,653,763

SUBUNIT IMMERSION VACCINES FOR FISH

BENCHMARK ANIMAL HEALTH L...

1. A vaccine for fish comprising an antigenic fusion protein, wherein the antigenic fusion protein has a leader sequence consisting of the amino acid sequence of residues 1-90 of SEQ ID NO:7, and an antigenic fragment comprising an amino acid sequence of a histone like protein (HLP) from Tenacibaculum maritimum (T. maritimum), Flavobacterium columnare (F. columnare) or Flavobacterium psychrophilum (F. psychrophilum);wherein the amino acid sequence of the HLP from T maritimum has the amino acid sequence of SEQ ID NO:2, wherein the amino acid sequence of the HLP from F. columnare has the amino acid sequence of SEQ ID NO:4, and wherein the amino acid sequence of the HLP from F. psychrophilum has the amino acid sequence of SEQ ID NO:6.
US Pat. No. 10,653,764

IMMUNOGENIC COMPOSITIONS FOR USE IN PNEUMOCOCCAL VACCINES

Pfizer Inc., New York, N...

1. A method of inducing an immune response to S. pneumoniae serotypes 9N, 9A and/or 9L in a subject, comprising administering to the subject an immunologically effective amount of an immunogenic composition comprising at least one glycoconjugate from S. pneumoniae serotype 9V, wherein said immunogenic composition further comprises glycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 14, 18C, 19A, 19F, and 23F, and wherein said immunogenic composition further comprises at least one glycoconjugate S. pneumoniae serotype selected from serotype 8, 10A, 11A, 12F, 15B, 22F, and 33F.
US Pat. No. 10,655,044

SELF-HEALING DURABLE CEMENT

Saudi Arabian Oil Company...

1. A cement slurry comprising:from 1% to 90% by weight of the cement of a cement precursor material based on a total weight of the cement slurry; and
from 1% to 40% by weight of the cement of a swelling additive based on the total weight of the cement slurry,
where the swelling additive comprises (a) at least one micronized rubber in an amount from 50.0% to 95.0% by weight of the cement, and (b) comprises a combination of at least one distillate and at least one solvent-refined heavy paraffinic in an amount from 5.0% to 15.0% by weight of the cement.
US Pat. No. 10,653,765

VACCINE FOR PROPHYLAXIS OR TREATMENT OF AN ALLERGEN-DRIVEN AIRWAY PATHOLOGY

1. A method for preventing or reducing inflammation mediated by a Th2 response in a subject having inflammation mediated by a Th2 response, the method comprising the step of infecting the subject with a live Bordetella pertussis strain which is deficient for tracheal cytotoxin (TCT), pertussis toxin (PTX), and dermonecrotic toxin (DNT), wherein the step of infecting the subject results in the subject developing a Th1 immune response which prevents or reduces the development of inflammation mediated by a Th2 response.
US Pat. No. 10,655,045

SELF-HEALING DURABLE CEMENT

Saudi Arabian Oil Company...

1. A wellbore cementing system comprising:a tubular positioned in a wellbore such that an annulus is formed between a geological formation and the tubular; and
a cement structure positioned in at least a portion of the annulus, where
the cement structure comprises:
from 1% to 90% by weight of the cement of a cement precursor material based on a total weight of the cement structure, and
from 1% to 40% by weight of the cement of a swelling additive based on the total weight of the cement structure, where the swelling additive comprises (a) at least one micronized rubber in an amount from 50.0% to 95.0% by weight of the cement, and (b) comprises a combination of at least one distillate and at least one solvent-refined heavy paraffinic in an amount from 5.0% to 15.0% by weight of the cement.
US Pat. No. 10,653,766

USE OF OIL AND WATER EMULSIONS FOR INCREASING B CELL RESPONSES WITH MODIFIED VACCINIA ANKARA VIRUS

1. A pharmaceutical composition for inducing vaccinia neutralizing antibodies in an animal comprising a dose of at least 2×107 TCID50 of a recombinant modified vaccinia Ankara (MVA) virus comprising a nucleic acid sequence encoding an antigen selected from the group consisting of:(a) an antigen of a yellow fever virus; and
(b) an antigen of RSVin an emulsion comprising oil and water, wherein the composition induces at least a 2-fold higher level of vaccinia neutralizing antibodies at 26 days after immunization when compared to the same composition in the absence of the emulsion.
US Pat. No. 10,654,790

RECOVERY PROCESS FOR FUNCTIONALIZED COMPOUND REACTION PRODUCT

The Scripps Research Inst...

1. A process for recovery of a functionalized compound reaction product that is soluble in a water-immiscible organic solvent comprisingcontacting (i) an oxidizing electrophile comprising a main group element selected from the group consisting of thallium, lead, bismuth, antimony, selenium, arsenic, tellurium, and a mixture thereof, and (ii) a compound comprising at least one C—H bond that is an alkane, a heteroalkane, or an arene, in an aqueous acidic medium to form a reaction milieu comprising a reaction product that is an alkane oxygenate, heteroalkane oxygenate, or arene oxygenate, respectively, wherein at least one C—H bond of the starting alkane, heteroalkane, or arene compound comprising at least one C—H bond is replaced with an oxygenate group, and wherein the reaction product is soluble in a water-immiscible organic solvent,
contacting the reaction milieu with a water-immiscible organic solvent that is a hydrocarbon solvent in which the reaction product is soluble,
separating the water-immiscible organic solvent from the reaction milieu, wherein the reaction product is dissolved in the water-immiscible organic solvent, and
separating the reaction product and the water-immiscible organic solvent.
US Pat. No. 10,653,767

ZIKA VIRUS MRNA VACCINES

ModernaTX, Inc., Cambrid...

1. A method comprising administering to a subject an immunogenic composition comprising a messenger ribonucleic acid (mRNA) that comprises an open reading frame (ORF) encoding a JEV signal peptide fused to a Zika virus (ZIKV) prME protein formulated in a lipid nanoparticle in an effective amount to induce in the subject a ZIKV prME-specific immune response, wherein the ORF comprises the sequence of SEQ ID NO: 1.
US Pat. No. 10,654,791

COMPOSITION OF MATTER POLYOLS FOR POLYURETHANE APPLICATIONS

PETROLIAM NASIONAL BERHAD...

1. A method of preparing a plurality of ester polyols, comprising:subjecting palm fatty acid distillate to oxidative ozonolysis to form a mixture comprising azelaic acid and a plurality of monocarboxylic acids;
esterifying the mixture formed during said subjecting step with at least two branched primary polyols to produce a plurality of ester polyols,
wherein the at least two branched primary polyols comprise 2-methyl-1,3-propanediol (2-MePG) and trimethylolpropane (TMP);
wherein the mixture and the at least two branched primary polyols comprise a reaction mixture having a hydroxyl/carboxyl ratio corresponding to a ratio of moles of OH groups to moles of —COOH groups, wherein the hydroxyl/carboxyl ratio is from about 1.10 to about 1.85; and
wherein the plurality of ester polyols are produced in the form of a composition that contains the plurality of ester polyols present in a single phase.
US Pat. No. 10,653,768

METHOD FOR PRODUCING RNA COMPOSITIONS

1. A method for producing a liquid composition comprising a nanoparticle comprising at least one RNA and at least one cationic or polycationic compound, wherein the method comprises the steps of:(a) providing a first liquid composition comprising at least one RNA,
(b) providing a second liquid composition comprising at least one cationic or polycationic compound, wherein the at least one cationic or polycationic compound is a cationic or polycationic peptide or a cationic or polycationic protein,
(c) introducing the first liquid composition and the second liquid composition into at least one reactor, wherein the first liquid composition and the second liquid composition are mixed with a blend time of 5 seconds or less, and
(d) recovering the product liquid composition comprising the nanoparticle comprising the at least one RNA and the at least one cationic or polycationic compound from the reactor.
US Pat. No. 10,653,769

IDNA VACCINES AND METHODS FOR USING THE SAME

MEDIGEN, INC., Frederick...

1. A homogeneous clonally pure live attenuated virus prepared from cultured cells transfected with a vector comprising DNA encoding: (a) an infectious RNA molecule that encodes a non-pathogenic alphavirus; and (b) two RNA dependent RNA polymerase promoters; wherein the two RNA dependent RNA polymerase promoters are operatively linked to one or more portions of a capsid and a glycoprotein of the infectious RNA molecule.
US Pat. No. 10,654,793

PRODUCTION METHOD FOR 1-AMINO CYCLOPROPANE CARBOXYLIC ACID NONHYDRATE

SUMITOMO CHEMICAL COMPANY...

1. A method of producing 1-aminocyclopropanecarboxylic acid non-hydrate, which comprisestreating 1-aminocyclopropanecarboxylic acid hydrochloride with a tertiary amine in the presence of a C3-C4 alcohol and water,
keeping the reaction mixture at 50° C. or below,
collecting the precipitated crystal of 1-aminocyclopropanecarboxylic acid 0.5 hydrate by filtration, and
heating the obtained crystal to 80 to 245° C.
US Pat. No. 10,655,049

METHOD AND MATERIALS TO CONVERT A DRILLING MUD INTO A SOLID GEL BASED LOST CIRCULATION MATERIAL

Saudi Arabian Oil Company...

1. A method for controlling loss circulation in a subterranean formation, the method comprising the steps of:circulating in a wellbore a nanosilica drilling fluid having a pH in a range of from about 8 to about 11 and a gel pH of less than 8, the nanosilica drilling fluid comprising an aqueous-based drilling mud and an alkaline nanosilica dispersion;
introducing into the nanosilica drilling fluid an amount of a chemical activator sufficient to produce a convertible drilling mud, where the chemical activator is an acid and where the pH of the convertible drilling mud is less than the gel pH; and
allowing the convertible drilling mud to convert into the solid gel lost circulation material.
US Pat. No. 10,653,770

BIOCHEMICALLY STABILIZED HIV-1 ENV TRIMER VACCINE

Beth Israel Deaconess Med...

1. An isolated nucleic acid molecule encoding at least one gp140 polypeptide, wherein said gp140 polypeptide comprises an amino acid sequence at least 98% identical to residues 1-708 of SEQ ID NO:2.
US Pat. No. 10,654,026

POLYMERIC SORBENTS FOR ALDEHYDES

3M Innovative Properties ...

10. A method of sorbing an aldehyde on a polymeric sorbent, the method comprising:providing a polymeric sorbent comprising a reaction product of
a) a hydrolyzed divinylbenzene/maleic anhydride polymeric material having carboxylic acid groups; and
b) a nitrogen-containing compound having at least two amino groups of formula —NHR wherein R is hydrogen or alkyl and wherein the nitrogen-containing compound is attached to the hydrolyzed divinylbenzene/maleic anhydride polymeric material with an ionic bond;
sorbing the aldehyde on the polymeric sorbent, the aldehyde being of Formula (I)
R2—(CO)—H  (I)wherein R2 is hydrogen, alkyl, vinyl, or aryl and wherein the molecular weight of the aldehyde of Formula (I) is no greater than 200 grams/mole.
US Pat. No. 10,655,050

METHOD AND MATERIALS TO CONVERT A DRILLING MUD INTO A SOLID GEL BASED LOST CIRCULATION MATERIAL

Saudi Arabian Oil Company...

1. A method for controlling loss circulation, the method comprising the steps of:introducing into a wellbore a nanosilica drilling fluid comprising water and an alkaline nanosilica dispersion;
introducing into the nanosilica drilling fluid an amount of a chemical activator comprising a water soluble hydrolysable polyester to produce a convertible drilling mud, where the convertible drilling mud has an initial pH between 8 and 11 upon formation; and
allowing the chemical activator to hydrolyze to produce an acid and reduce the pH of the convertible drilling mud to less than a gel pH, thereby converting the convertible drilling mud into a solid gel lost circulation material.
US Pat. No. 10,653,771

VACCINES AGAINST HERPES SIMPLEX VIRUS TYPE 2: COMPOSITIONS AND METHODS FOR ELICITING AN IMMUNE RESPONSE

GENOCEA BIOSCIENCES, INC....

1. An immunogenic composition comprising a pharmaceutically-acceptable carrier, an immunostimulatory amount of an adjuvant and a particulate composition comprising a polypeptide comprising an amino acid sequence having at least 90% identity to SEQ ID NO: 2, wherein the polypeptide does not comprise a full length ICP4 polypeptide.
US Pat. No. 10,654,795

METHOD FOR SYNTHESIZING KETOXIME

CHEMICAL TECHNOLOGY ACADE...

1. A method for synthesizing a ketoxime, comprising: performing a reaction on a ketone, ammonia and hydrogen peroxide by using a titanium-silicon molecular sieve as a catalyst to obtain the ketoxime in a system of an aqueous carbonate solution;wherein a reaction progress is judged and an optimal reaction ratio is determined by a real-time monitoring of a pH value in a reaction system during the reaction, and
wherein steps are as follows: gradually introducing a predetermined amount of the ammonia and a non-predetermined amount of the hydrogen peroxide into a three-phase mixed system composed of the ketone, the aqueous carbonate solution and the titanium-silicon molecular sieve, and monitoring the pH value in the reaction system by using an online pH meter; when the pH value returns to an initial pH of the aqueous carbonate solution, stopping dropwise adding the hydrogen peroxide, and after the reaction is completed, putting aside the reaction system for layering, wherein a product extracted from an upper layer of the reaction system is the ketoxime, and a lower layer of the reaction system is an aqueous phase.
US Pat. No. 10,655,051

USE OF PARTICULATE OR FIBROUS MATERIALS IN GRAVEL PACK APPLICATIONS

M-I L.L.C., Houston, TX ...

8. A method comprising:running a sand control screen assembly to a selected depth within the uncased section of the wellbore to facilitate a gravel packing operation; and
introducing a gravel pack slurry comprising polyhydroxycarboxylic acid into the wellbore to facilitate gravel packing operations, wherein the polyhydroxycarboxylic acid is a polymer formed from one or more monomers selected from a group consisting of malic acid, lactic acid, gluconic acid, citric acid, mandelic acid, saccharic acid, mucic acid, and tartaric acid, wherein the polyhydroxycarboxylic acid hydrolyzes at a temperature ranging from about 150° F. to about 170° F.
US Pat. No. 10,653,772

HEPATITIS B TREATMENT VACCINE ON THE BASIS OF INACTIVATED, WHOLE RECOMBINANT HANSENULA POLYMORPHA CELLS EXPRESSING HBSAG

Hemu Wang, Tianjin (CN)

1. A hepatitis B therapeutic vaccine based on inactivated whole recombinant Hansenula polymorpha cells expressing HBsAg, wherein the hepatitis B therapeutic vaccine uses the inactivated whole recombinant Hansenula polymorpha cells as an adjuvant, the intracellular expression level of HBsAg in the recombinant Hansenula polymorpha cells is 6-10 ?g HBsAg per 108 cells; and each HBsAg has 19 HBsAg-specific CTL epitopes, and the DNA sequence expressed by the recombinant Hansenula polymorpha cell is shown as SEQ ID NO: 1.
US Pat. No. 10,654,028

CATALYST FOR CATALYZING FORMALDEHYDE OXIDATION AND THE PREPARATION AND USE OF THE SAME

Lumileds Holding B.V., S...

1. A catalyst comprising manganese oxides wherein the manganese oxides comprise:MnO in an amount of 40-60 mole %, based on mole of Mn;
Mn2O3 in an amount of 40-60 mole %, based on mole of Mn; and
Mn3O4 in an amount of 1-10 mole %, based on mole of Mn, and wherein the total mole of Mn in the catalyst is 100 mole %.
US Pat. No. 10,658,126

CAPACITOR ELECTRODE MATERIAL, METHOD FOR PRODUCING SAME, AND ELECTRIC DOUBLE LAYER CAPACITOR

SEKISUI CHEMICAL CO., LTD...

1. A capacitor electrode material comprisingresin-remaining partially exfoliated graphite obtained by pyrolyzing a resin in a composition in which the resin is previously fixed to graphite or primary exfoliated graphite by grafting or adsorption, the resin-remaining partially exfoliated graphite having a structure in which graphite is partially exfoliated, with part of the resin remaining; and
a binder resin,
wherein when an amount of methylene blue adsorbed per g of the resin-remaining partially exfoliated graphite (?mol/g) is y, the amount of methylene blue adsorbed being measured based on a difference between an absorbance of a methanol solution of methylene blue at a concentration of 10 mg/L and an absorbance of a supernatant liquid obtained by introducing the resin-remaining partially exfoliated graphite into the methanol solution of methylene blue followed by centrifugation, and a BET specific surface area (m2/g) of the resin-remaining partially exfoliated graphite is x, a ratio y/x is 0.15 or more, and the BET specific surface area of the resin-remaining partially exfoliated graphite is 40 m2/g or more.
US Pat. No. 10,653,773

PEANUT FORMULATIONS AND USES THEREOF

Aimmune Therapeutics, Inc...

1. A method of making a pharmaceutical composition for treatment of peanut allergy in a subject, comprising:(1) assaying, in a quality control process, a composition comprising peanut flour, said assaying comprising:
determining the concentrations of Ara h 1, Ara h 2, and Ara h 6 in a composition comprising peanut flour by high-performance liquid chromatography (HPLC);
comparing the concentrations of Ara h 1, Ara h 2, and Ara h 6 in the composition to the concentrations of Ara h 1, Ara h 2, and Ara h 6 in a reference standard; and
identifying the composition as suitable for treatment of peanut allergy based on the comparison to the reference standard; and
(2) formulating the composition comprising peanut flour identified in step (1) for oral administration.
US Pat. No. 10,654,798

PROCESS FOR CONTINUOUS INDUSTRIAL SYNTHESIS OF ALKANE-SUPHONICACID

ARKEMA FRANCE, Colombes ...

1. A process for the continuous industrial preparation of alkanesulphonic acid of formula CnH2n+1SO3H from the alkane of formula CnH2n+2, wherein n represents an integer between 1 and 20 inclusive, said process comprising at least the following steps:a) loading of alkanesulphonic acid CnH2n+1SO3H, wherein n is as defined above, in a reactor,
b) heating said alkanesulphonic acid at a temperature between 25° C. and 120° C.,
c) introducing a quantity of sulphur trioxide so that the molar ratio (alkanesulphonic acid)/(sulphur trioxide) is between 70/30 and 95/5,
d) introducing the alkane under a pressure between 4 MPa and 15 MPa,
e) introducing a radical initiator,
f) continuous conducting of the reaction, and simultaneously or in any order performing the following three sub-steps f1), f2) and f3):
f1) addition of sulphur trioxide in order to maintain the initial molar ratio (alkanesulphonic acid)/(sulphur trioxide) defined in step c),
f2) addition of alkane in order to maintain a molar ratio (alkane)/(sulphur trioxide) between 4/1 and 2/1, and
f3) continuous withdrawal of the alkanesulphonic acid of formula CnH2n+1SO3H, and
g) recovery of the alkanesulphonic acid of formula CnH2n+1SO3H after optional separation of unreacted reagents, and optionally any undesired by-products.
US Pat. No. 10,655,054

FOAM-FORMING SURFACTANT COMPOSITIONS

Cytec Industries Inc., P...

1. A foam-forming surfactant composition comprising at least one sulfosuccinamate surfactant compound of formula:R—NX—CO—CHY1—CHY2—CO—O?M4+,  (Formula I),
where
Y1 is H and Y2 is (SO3?M3+), or Y1 is (SO3?M3+) and Y2 is H,
R is a linear or branched or cyclic aliphatic radical having from four to twenty-four carbon atoms, and
X is an alkylcarboxylate group —(CRaRb)—COO?M2+ where Ra and Rb may both be H, or one of Ra or Rb is H and the other is —CH2—COO?M1+, where M1+ and M2+ and M3+ and M4+ may be the same or different, and each is independently selected from the group consisting of the cations of the chemical elements of groups 1 and 2 of the Periodic Table of the Elements, consisting of the alkali metals, and the earth alkali metals, and from ammonium NH4+; and
at least one monoester sulfosuccinate surfactant compound of formula
R1—O—CO—CHY3—CHY4—CO—O—R2,  (Formula III),
where
Y3 is H and Y4 is (SO3?M+), or Y3 is (SO3?M+) and Y4 is H;
one of R1 and R2 may be selected from the group consisting of linear or branched or cyclic aliphatic radicals having from four to twenty-four carbon atoms, and
the other of R1 and R2 is a hydrogen atom or an alkali metal selected from the group consisting of the cations of the chemical elements of groups 1 and 2 of the Periodic Table of the Elements, consisting of the alkali metals, and the earth alkali metals, and from ammonium NH4+, and
M+ is selected from the group consisting of the cations of the chemical elements of groups 1 and 2 of the Periodic Table of the Elements, consisting of the alkali metals, and the earth alkali metals, and from ammonium NH4+.
US Pat. No. 10,653,775

ANTI-GLUCOSAMINIDASE PASSIVE IMMUNIZATION FOR STAPHYLOCOCCUS AUREUS INFECTIONS

University of Rochester, ...

1. An isolated humanized monoclonal antibody or an antigen binding portion thereof that binds specifically to a Staphylococcus aureus glucosaminidase (Gmd) and comprises (i) the complementarity determining region sequences of the VH domain of SEQ ID NO: 1 and the VL domain of SEQ ID NO: 8, or (ii) the complementarity determining region sequences of the VH domain of SEQ ID NO: 2 and the VL domain of SEQ ID NO: 9.
US Pat. No. 10,654,031

COPPER CHA ZEOLITE CATALYSTS

BASF Corporation, Florha...

1. An ammonia SCR catalyst article comprising a substrate having deposited thereon a copper-containing aluminosilicate zeolite having a CHA crystal structure, wherein the zeolite contains at least about 2.00 weight percent copper, expressed as copper oxide, and has a mole ratio of silica to alumina from about 20 to about 40, wherein the CHA crystal structure is characterized by lattice parameters determined from an X-ray powder diffraction pattern, and wherein the hydrothermal stability of the lattice parameters of the CHA crystal structure is confirmed by a hydrothermal aging test, and wherein the hydrothermal aging test comprises subjecting the catalyst article to hydrothermal aging by aging the catalyst article in the presence of 10% H2O at 800° C. for 48 hours, and wherein the lattice parameters of the CHA crystal structure after said hydrothermal aging test are within 1% of the lattice parameters of the CHA crystal structure prior to said hydrothermal aging test.
US Pat. No. 10,656,079

UV SOLID STATE DETECTION AND METHODS THEREFOR

MICRO DETECT, INC., Tust...

1. A method for detecting a molecule-molecule interaction, comprising:detecting a molecular interaction reaction between a first molecule and a second molecule, without labeling first and second molecules, in a dry environment, by measuring light absorption in at least one of light transmission mode and light reflection mode, wherein the dry environment comprises a test surface selected from the group consisting of a plate, a bead, a film, and a porous membrane.
US Pat. No. 10,653,777

PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM

AXSOME THERAPEUTICS, INC....

1. A method of treating migraine comprising: selecting a human migraine patient with a history of inadequate response to prior migraine treatments, and orally administering a dosage form to the migraine patient, wherein the dosage form comprises a combination of: 1) a complex of meloxicam with a sulfobutyl ether ?-cyclodextrin (SBE?CD), 2) a bicarbonate, and 3) a rizatriptan, wherein the human migraine patient experiences reduction in nausea that lasts at least 24 hours after the dosage form is orally administered to the human migraine patient.
US Pat. No. 10,654,289

INKSET FOR INK JET TEXTILE PRINTING AND INK JET TEXTILE PRINTING METHOD

Seiko Epson Corporation, ...

1. An ink set for ink jet textile printing, comprising:a first ink having a pigment and a resin; and
a second ink having a pigment, a resin and an emulsifier,
wherein the emulsifier includes an anionic emulsifier represented by the following general formula (1),
R1—O—(CH2—CH2—O)n-A  (1)
(in the general formula (1), R1 represents a substituted or un-substituted hydrocarbon group having 18 or more carbon atoms, A represents —SO3M, —PO3HM, or —CH2COOM, M represents alkali metal, ammonium, or alkanolamine, and n represents an integer from 2 to 20), and
wherein a content of an emulsifier in the first ink is less than 0.03% by mass.
US Pat. No. 10,653,778

COMPOSITIONS AND METHODS FOR TREATING CHRONIC INFLAMMATION AND INFLAMMATORY DISEASES

Infirst Healthcare Limite...

1. A pharmaceutical composition comprising:a) a peroxisome proliferator-activator receptor gamma (PPAR-?) agonist;
b) a pharmaceutically-acceptable lipid in an amount of at least 50% by weight of the pharmaceutical composition, the pharmaceutically-acceptable lipid comprising a pharmaceutically-acceptable hard fat in an amount of at least 30% by weight of the pharmaceutical composition, the hard fat including a triglyceride or a triester of glycerol and a pharmaceutically-acceptable liquid fat in an amount of at least 20% by weight of the pharmaceutical composition, the liquid fat including a monoglyceride or an acetylated monoglyceride; and
c) a pharmaceutically-acceptable liquid polyethylene glycol (PEG) polymer in an amount less than about 20% by weight of the pharmaceutical composition,wherein the pharmaceutical composition is formulated to be a solid at a temperature of about 15° C. or lower and has a melting point temperature of about 25° C. or higher.
US Pat. No. 10,653,779

FORMULATIONS WITH REDUCED OXIDATION

GENENTECH, INC., South S...

1. A liquid formulation comprising a protein and a compound derived from tryptophan wherein the compound prevents oxidation of the protein in the liquid formulation, wherein the compound shows reduced hydrogen peroxide production compared to tryptophan, and wherein the compound is selected from the group consisting of 5-hydroxy-tryptophan, 5-hydroxy indole, 7-hydroxy indole, and serotonin.